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-Secretase is a four subunit, 20-pass transmembrane aspartyl protease that has 
sustained a great deal of scientific scrutiny due to its role in disease: -Secretase 
cleaves amyloid precursor protein, catalyzing the formation of amyloid plaques, which 
contribute to Alzheimer’s disease (AD) pathogenesis, and it also cleaves Notch, the 
abnormal signaling of which can lead to cancer. -Secretase has been reported to 
process over 90 other substrates, all of which are type 1 transmembrane proteins. As a 
result of -secretase’s enzymatic promiscuity and role in many pivotal cellular 
processes, it is a difficult target for drug development. -Secretase inhibitors (GSIs), 
which pan-inhibit -secretase so that it cannot cleave any of its substrates, are poor 
candidates for AD therapy as they cause toxicity. Still, GSIs are promising candidates 
for cancer. -Secretase modulators (GSMs), which reduce formation of the 
amyloidogenic Aβ42 without affecting Notch signaling, are promising therapeutics for 
AD, as they avoid the Notch-associated toxicities seen with GSI treatment. In order to 
develop safe and effective therapies for AD and cancer we must gain a deeper 
understanding of -secretase biology and the mechanism of action of GSIs/GSMs.  
To understand the process of -secretase activation we developed CBAP-BPyne, a 
clickable photoaffinity probe that inhibits not only -secretase activity, but also 
endoproteolysis, an event required for formation of an active -secretase complex. We 
found that CBAP-BPyne specifically labels PS1-NTF and signal peptide peptidase 
(SPP). Endoproteolysis is not well characterized and CBAP-BPyne is a valuable tool 
with which to further explore its mechanism.  
To provide insight into the mechanism of action of GSIs/GSMs, we studied the impact 
of these compounds on the active sites of their target enzyme, -secretase, and on an 
off-target enzyme, SPP. We found that GSIs/GSMs impact the active site architecture 
of not only -secretase, but also SPP, suggesting that they may lead to a change in SPP 
activity and function, potentially causing toxicity in the clinic. Furthermore, we 
identified the binding site of BMS-708163, a clinically relevant GSI, on -secretase, 
marking the first time that a GSI/GSM was mapped onto its target with high precision.  
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CHAPTER 1 
Introduction (Gertsik et al., 2014b) 
1.1 The discovery and importance of γ-secretase 
Proteolysis is a process by which proteins are cleaved into smaller fragments through 
hydrolysis of the peptide bond. This process is catalyzed by enzymes, which have 
evolved to quickly and efficiently cleave target proteins to enable signaling, 
transcription, degradation, clearance, etc. Until the mid 1990s, proteolysis was 
believed to be carried out by soluble proteases, as a water molecule is required for 
hydrolysis. However, three classes of transmembrane proteases – metallo, aspartyl, 
and serine – were discovered between 1997 and 2001 (Rawson et al., 1997;Esler et al., 
2000;Li et al., 2000b;Urban et al., 2001). Moreover, these proteases were shown to 
have active sites deep within the lipid membrane, where they hydrolyze 
transmembrane regions. This was revolutionary at the time of its discovery, as it was 
hard to imagine how a reaction that requires a water molecule can take place in a 
region as hydrophobic as the membrane. We now know that these enzymes can 
coordinate a water molecule in a hydrophilic pocket in order to catalyze cleavage. It is 
no surprise then that the enzymes all have multiple transmembrane domains (TMDs) 
which can arrange to form a local environment conducive to hydrolysis.  
Regulated intramembrane proteolysis (RIP) is a highly conserved mechanism that 
controls many cellular processes. The presence of intramembrane-cleaving proteases 
in the genomes of evolutionarily distinct species underscores the highly conserved 
nature of the process they catalyze (Freeman, 2008). There has been much speculation 
regarding the fundamental, overarching role of γ-secretase in RIP. Because it was 
discovered in a genetic linkage Familial Alzheimer’s disease (FAD) study, γ-secretase 
was initially associated with amyloid precursor protein (APP) cleavage and 
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amyloidogenic Aβ42 production in the brain. Later, when γ-secretase was shown to 
cleave Notch, forming Notch intracellular domain (NICD) that travels to the nucleus 
to induce transcription (De Strooper et al., 1999), scientists became excited by the idea 
that γ-secretase cleavage of its substrates may generally result in the release of 
transcriptional regulators. However, this idea was thwarted by the lack of evidence for 
the function of APP intracellular domain (AICD) as a transcriptional regulator. Next, 
scientists adopted a more general hypothesis that γ-secretase substrates are involved in 
signaling. Again this hypothesis needed further examination, as some ectodomain 
shedding and subsequent γ-secretase cleavage events, like APP proteolysis, appear to 
be constitutive and many ICDs are rapidly degraded (Cupers et al., 2001;Edbauer et al., 
2002). Another hypothesis for the physiological relevance of γ-secretase is that it 
initially functioned as a “proteasome of the membrane,” clearing the transmembrane 
region of unwanted proteins; some of the released fragments evolved to become 
signaling molecules while others are still destined for degradation (reviewed in 
(Kopan and Ilagan, 2004)).  
APP and Notch are the most widely studied γ-secretase substrates. APP undergoes 
sequential proteolytic processing by β-secretase, a membrane bound aspartyl protease 
called β-site APP cleaving enzyme 1 (BACE-1), and γ-secretase to generate amyloid 
beta (Aβ) peptides. Notch, a protein that resides on the surface of signal-receiving 
cells as a heterodimeric receptor, is also subject to a series of proteolytic cleavages 
that result in NICD nuclear translocation and subsequent transcription (Figure 1.1). 
The scientific scrutiny sustained by both APP and Notch results from their role in 
disease: aberrant γ-secretase cleavage of APP and Notch can lead to Alzheimer’s 
disease (AD) and cancer, respectively. γ-Secretase is an important potential drug target 
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for both diseases and γ-secretase inhibitors (GSIs) and modulators (GSMs) are in 
clinical trials for cancer and AD, respectively. 
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Figure 1.1. Proteolytic processing of APP and Notch. Mature Notch receptors are 
activated by binding to ligands (Jagged-1, -2 and Delta-like -1, -3, -4) located on 
adjacent signal-presenting cells. An induced conformational change exposes a 
cleavage site (S2) for ADAM family metalloproteases that cleave Notch at an 
extracellular, membrane-proximal region. The membrane-bound Notch segment that 
results from this cleavage, known as Notch Intracellular Truncation domain (NEXT), 
is a γ-secretase substrate (Kopan and Ilagan, 2009). γ-Secretase performs the 
subsequent cleavage at S3 (De Strooper et al., 1999), releasing Notch intracellular 
domain (NICD) from the membrane and allowing for signal transduction through 
binding with the CSL (CBL-1, Su(H), Lag-1) (Schroeter et al., 1998;Struhl and 
Adachi, 1998) family of DNA binding proteins. APP undergoes sequential proteolytic 
processing first by β-secretase (BACE-1, aspartyl protease) and then by γ-secretase, in 
the amyloidogenic pathway. The first cleavage results in ectodomain shedding in 
which the amino-terminal of APP is removed, yielding a soluble APP derivative 
(sAPPβ) and a carboxy-terminal membrane stub known as βCTF (C99). βCTF is a 
substrate for γ-secretase, and is cleaved in its transmembrane domain to form AICD 
and the potentially toxic Aβ. Mutations in PS (the catalytic subunit of γ-secretase) and 
APP can lead to increases in the Aβ42 to Aβ40 ratio, resulting in Aβ deposition and 
plaque formation. 
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1.2 Alzheimer’s disease – its causes and risk factors 
Alzheimer’s disease  
AD, the most common form of dementia, causes dysfunctions of memory, judgment, 
and daily tasks. In today’s rapidly aging population AD has become a major public 
health concern. It is the 6th leading cause of death in the U.S., and while deaths from 
other major diseases have been on the decline, AD related deaths continue to climb, 
affecting 5.3 million Americans, of whom 5.1 million are over 65 (Alzheimer's 
Association, 2015). By 2050, 13.8 million people over 65 are expected to have the 
disease. AD cost the nation $226 billion in 2015 alone, and this number takes into 
account only direct cost of care, without considering the many indirect losses 
associated with the disease. There is no cure for AD and no way to slow disease 
progression. Current treatments include cholinesterase inhibitors and NMDA 
antagonists. 
Histopathologically, AD is characterized by the presence of extracellular amyloid 
plaques (Glenner and Wong, 1984a;b) and intracellular neurofibrillary tangles (NFTs) 
(Grundke-Iqbal et al., 1986;Nukina and Ihara, 1986) in the brain. The amyloid plaques 
are mainly composed of β-amyloid peptides (Aβ), which are cleavage products of 
amyloid precursor protein (APP). These peptides can begin to aggregate when the 
production of the highly amyloidogenic Aβ42 (42 amino acids) increases with respect 
to production of Aβ40 (40 amino acids). The NFTs are composed of 
hyperphosphorylated tau, a microtubule-binding protein that forms insoluble filaments 
(reviewed in (Morris et al., 2011)).  
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The amyloid cascade hypothesis 
According to the amyloid cascade hypothesis, AD is driven by Aβ accumulation 
(Hardy and Allsop, 1991). Specifically, Aβ accumulation is believed to be the 
upstream event that leads to plaque and NFT formation, neuronal cell death, the 
inflammatory response, and cognitive impairment (Figure 1.2). Aβ can exist in many 
forms, including monomers, dimers, oligomers, fibrils, and plaques. Although 
insoluble plaques were initially considered to be the culprit of the disease, it is now 
generally recognized that soluble Aβ may actually be the pathogenic species (Selkoe, 
2002). 
Strong genetic evidence for the amyloid cascade hypothesis exists. An abundance of 
autosomal dominant AD mutations have been identified in APP (Goate et al., 1991) 
and PS (Levy Lahad et al., 1995;Sherrington et al., 1995), which are key players in the 
pathway that leads to Aβ formation. We now know of 30 APP mutations, 9 APP 
duplications, 211 PS1 mutations, and 33 PS2 mutations that lead to early onset FAD 
(Cruts et al., 2012) (www.molgen.ua.ac.be/ADMutations) (Figure 1.2). It is tempting 
to hypothesize that these mutations lead to an overall increase in Aβ, because such a 
finding would directly link increased Aβ to AD. However, not all of these mutations 
are gain of function (where “gain of function” means increased Aβ). In fact, many of 
them cause decreased levels of overall Aβ. Significantly, all of these mutations 
increase the Aβ42:Aβ40 ratio (Scheuner et al., 1996) 
(www.molgen.ua.ac.be/ADMutations). This suggests that the toxic event is an 
increase in the Aβ42:Aβ40 ratio, and not necessarily in total Aβ. Aβ42 is more 
hydrophobic than the shorter Aβ peptides and is enriched in Aβ plaques (Iwatsubo et 
al., 1994). Small increases in Aβ42:Aβ40 without changes in total Aβ enhance 
aggregation of the neurotoxic peptides (Kuperstein et al., 2010). Similarly, decreases 
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in Aβ40 increase Aβ42:Aβ40 and may result in amyloidogenesis (Deng et al., 
2006;Kumar-Singh et al., 2006;Wang et al., 2006;Kim et al., 2007;Yan and Wang, 
2007;Jan et al., 2008;Murray et al., 2009). 
A recent genome-wide association study (GWAS) of an Icelandic population revealed 
the existence of a mutation in APP that protects against AD (Jonsson et al., 2012). The 
A673T mutation is adjacent to the β-secretase cleavage site on APP and reduces the 
amount of β-cleavage, thereby reducing Aβ production. This discovery has cemented 
the importance of Aβ in AD, revealing that changes in Aβ production can mean the 
difference between early onset disease and immunity. 
Risk factors 
While the autosomal dominant mutations detailed above have provided insight into 
disease etiology, they account for a very small fraction of AD cases. Most commonly, 
AD presents as a late onset, sporadic, multi-factorial condition. The biggest risk factor 
for AD is age. The second biggest is the APOE4 allele (Corder et al., 1993) (Figure 
1.2). The APOE gene has three common alleles (e2, e3, e4) with e3 being the most 
frequent (Ward et al., 2012). The APOE proteins derived from these alleles differ by 
only one or two amino acids, yet they have strikingly different impacts on disease. 
Homozygotes for APOE4 have a higher risk of AD than do heterozygotes, and 
heterozygotes have a higher risk than non-carriers. Conversely, APOE2 may be 
protective (Berlau et al., 2009). While the mechanism of action is poorly understood, 
one possibility is that APOE4 induces increased aggregation and impaired clearance of 
Aβ while APOE2 has the opposite effect (Holtzman et al., 2000;Kim et al., 2009).  An 
additional risk factor for AD is being a female. Interestingly, the reverse is true of 
Parkinson’s disease. 
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Figure 1.2. The Aβ cascade hypothesis. Mutations in APP and presenilin (PS) (red) 
are fully penetrant and cause FAD. The number of FAD mutations discovered in each 
of these proteins is shown in parentheses. The number of mutations is large, but the 
percentage of FAD cases compared to total AD cases is small. Risk factors such as 
APOE4 alleles, age, and gender contribute to over 95% of all AD cases. AD is 
believed to be driven by an imbalance/overabundance of Aβ, which leads to 
downstream consequences such as NFT formation, neuronal cell death, and dementia. 
Today’s treatments focus on the symptoms and not on the processes involved in early 
disease progression. 
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1.3 γ-Secretase cleaves APP  
APP proteolysis falls into one of two pathways: either APP is cleaved sequentially by 
α and γ-secretase in the nonamyloidogenic pathway, generating P3, sAPPα, and AICD, 
or it is cleaved by β and γ-secretase in the amyloidogenic pathway, generating Aβ, 
sAPPβ, and AICD (Figure 1.3). α-Secretase cleavage of APP occurs in the Aβ region, 
which precludes Aβ production, so the choice to preferentially undergo more α 
cleavage can mean the difference between healthy and disease states. What factors 
determine the decision to participate in one pathway over the other? It has been 
suggested that α-secretase competes with β-secretase for the APP substrate, thereby 
lowering Aβ formation (Lammich et al., 1999;Skovronsky et al., 2000;Postina et al., 
2004). However, compelling evidence exists for an alternate mechanism in which α-
secretase cleavage results in formation of a substrate inhibitory domain (ASID) within 
αCTF that binds to an allosteric site in γ-secretase, thereby inhibiting γ-secretase 
processing of βCTF and ultimate Aβ production (Tian et al., 2010b). In this model, α-
secretase plays a dual anti-amyloidogenic role: first, it cleaves APP in the Aβ region, 
thereby directly precluding Aβ formation, and second, it initiates a feedback loop in 
which αCTF binds γ-secretase and acts as a γ-secretase modulator which specifically 
lowers Aβ production. ASID is also present in βCTF, suggesting that the product of β-
secretase cleavage is imbued with γ-secretase-regulating capacity as well. The Flemish 
FAD mutation, located in the ASID domain, interferes with βCTF’s inhibitory potency, 
leading to increased Aβ (Tian et al., 2010a). ASID is the first example of a substrate’s 
inherent ability to regulate γ-secretase, but it is probably not the last (reviewed 
in(Zhang and Xu, 2010)). 
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Figure 1.3. γ-Secretase cleavage of APP can follow either the amyloidogenic or 
non-amyloidogenic pathway. Amyloidogenic pathway: The ectodomain of APP is 
cleaved by β-secretase, which results in production of sAPPβ and βCTF. βCTF is then 
cleaved by γ-secretase to produce Aβ peptides of various lengths and AICD. Non-
amyloidogenic pathway: The ectodomain of APP is cleaved by α-secretase, which 
results in production of sAPPα and αCTF. αCTF is then cleaved by γ-secretase to 
produce the non-amyloidogenic p3 species and AICD. 
1.4 The γ-secretase complex: composition and regulation  
Biochemical studies indicated that γ-secretase activity is catalyzed by the presenilin 
(PS)-containing macromolecular complex (Li et al., 2000b). The search for other 
components of the complex revealed three additional proteins: nicastrin (Nct), anterior 
pharynx-defective-1 (Aph1), and presenilin enhancer-2 (Pen2) (Yu et al., 2000;Francis 
et al., 2002;Goutte et al., 2002). It has since been established that these four proteins 
constitute the mature γ-secretase complex (De Strooper, 2003;Selkoe and Wolfe, 
2007), and their stepwise assembly, followed by endoproteolysis of PS into amino-
terminal (PS-NTF) and carboxy-terminal fragments (PS-CTF), is necessary for active 
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complex formation (Takasugi et al., 2003) (Figure 1.4). Recent reports of high 
resolution cryo-electron microscopy structures of intact human γ-secretase and 
identification of novel γ-secretase modulating mechanisms have provided insight into 
the flexibility and complexity of this enzyme (Lu et al., 2014;Bai et al., 2015a;Bai et 
al., 2015b).       
γ-Secretase processing of its substrates produces distinct amino and carboxy termini 
with variable functions; some products of γ-secretase cleavage function as 
transcriptional regulators while others are thought to play roles in signaling, cell 
adhesion, and cytoskeletal dynamics. As the list of putative γ-secretase substrates 
continues to grow, now reaching over 90 reported proteins (Haapasalo and Kovacs, 
2011), the lack of homology between these substrates becomes increasingly apparent: 
other than the fact that they are all type I transmembrane proteins that have undergone 
ectodomain shedding, γ-secretase substrates are surprisingly dissimilar (Beel and 
Sanders, 2008;Lleo, 2008). (Of note, how many of these substrates are actually 
processed by γ-secretase in vivo remains to be investigated.) Not only are the 
substrates themselves widely variable, but cleavage of some substrates (i.e. CD44 and 
Notch1) (Lammich et al., 2002;Okochi et al., 2002) leads to release of peptides with 
variable carboxy-terminal ends, further confirming γ-secretase’s astounding 
promiscuity. In short, γ-secretase not only cleaves many substrates, but it cleaves the 
same substrate in many places. The permutation is daunting, and may be evolutionary 
evidence for γ-secretase’s initial function in regulated degradation of transmembrane 
proteins (Kopan and Ilagan, 2004). However, even if γ-secretase was ever simply a 
“proteasome of the membrane,” its function now is certainly much more complex. As 
a result, γ-secretase regulation must be at least as intricate and diverse as its function.  
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γ-Secretase activity is regulated by the assembly of its four essential subunits as well 
as at the level of the entire complex. Extensive investigation of the former revealed 
that each of the four essential γ-secretase subunits is tightly and independently 
controlled. More recently, the importance of regulation of the entire complex has 
emerged, suggesting additional levels of modulation in γ-secretase function. CD147, 
phospholipase D1, TMP21, GPR3, γ-secretase activating protein (GSAP), syntaxin-1, 
Arc, voltage-dependent anion channel 1 (VDAC1), contactin-associated protein 1 
(CNTNAP1), TPPP, NDUFS7, Erlin-2, β-arrestin-1, β-arrestin-2, Hif-1α, and Nexin 
27 have all been implicated as nonessential γ-secretase interacting partners that 
modulate γ-secretase activity (Zhou et al., 2005;Cai et al., 2006;Chen et al., 
2006;Thathiah et al., 2009;He et al., 2010;Teranishi et al., 2010;Wu et al., 
2011;Frykman et al., 2012;Hur et al., 2012;Teranishi et al., 2012;Liu et al., 
2013;Thathiah et al., 2013;Villa et al., 2014;Wang et al., 2014).  However, some of 
this work is controversial and it remains to be seen whether many of these proteins 
play a specific and functionally significant role in γ-secretase regulation (Vetrivel et 
al., 2007;Vetrivel et al., 2008;Hussain et al., 2013). Despite the uncertainty, much can 
be learned from the way in which a promiscuous enzyme is spatially and temporally 
modulated by its essential subunits and nonessential cofactors.  
γ-Secretase is regulated by its four essential subunits 
γ-Secretase’s enzymatic promiscuity may on first glance suggest a kind of rampant 
cleavage activity that indiscriminately chops up anything in its way. Actually, the 
opposite is true. γ-Secretase may be flexible in its choice of substrate and cleavage site, 
but its activity is controlled in the cell by a variety of mechanisms, not the least of 
which is regulation of active complex formation. Perhaps the most basic evidence for 
this is the finding that γ-secretase activity cannot be increased through the 
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overexpression of PS alone (Levitan et al., 2001), and can be reconstituted only when 
all four γ-secretase subunits are present (Edbauer et al., 2003). Put another way, the 
selective ablation of any one of the essential subunits leads to a loss of active complex 
and enzymatic activity (De Strooper, 2003). This implies that each subunit must be in 
the proper place at the right time in order for γ-secretase to form. However, the 
presence of all four essential subunits does not guarantee active complex formation. 
This is evidenced by the fact that only a small fraction of steady-state γ-secretase in 
the cell is actually catalytically active (Beher et al., 2003;Lai et al., 2003;Gu et al., 
2004). Furthermore, while overexpression of wild type PS1 in mice is sufficient to 
increase the amount of γ-secretase complex and protease activity in brains, this is not 
the case in cellular studies (Li et al., 2011). The implication is that even when all four 
subunits are in complex with one another, additional events may be necessary to 
render that complex catalytically active. Some of these events are initiated by 
modulatory proteins, discussed briefly in the “γ-secretase is regulated by modulatory 
proteins” section below. 
The issue is further complicated by the fact that active complexes fall into a wide 
range of activities with respect to both catalytic efficiency and substrate specificity. 
Despite the deceptive language used here to describe γ-secretase as “active” and 
“inactive,” γ-secretase activity is far from a simple on/off switch. Assuming γ-
secretase complexes have a 1:1:1:1 ratio of all essential subunits (Sato et al., 2007), at 
least four different complexes can be theoretically constructed, keeping in mind the 
existence of PS and Aph1 (PS1/PS2 and Aph1a/Aph1b) isoforms and the finding that 
these isoforms do not co-exist in the same complexes (Lai et al., 2003;Shirotani et al., 
2004). Identification of the Aph1a splice variants (Aph1aS and Aph1aL) increased the 
permutation further, to a total of six (Shirotani et al., 2004). Experimentally, different 
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γ-secretase complexes have indeed been identified and shown to vary in catalytic 
activity (Lai et al., 2003). Some tissue specificity has been observed in the expression 
of Aph1 and PS variants, but this alone cannot account for determining which 
complex gets formed and which does not, especially since different variants of the γ-
secretase complex exist dynamically in the same tissue, and even in the same cell line 
(Placanica et al., 2009a;Placanica et al., 2009b). More complicated mechanisms of 
regulating complex formation pervade, such as the ability of one isoform/mutant to 
outcompete the other for limiting factors (Placanica et al., 2009a).  
The inherent complexity of γ-secretase can be put into perspective by comparing it to 
signal peptide peptidase (SPP), the only other family of intramembrane aspartyl 
proteases. Unlike γ-secretase, SPP appears to function alone without the participation 
of other protein co-factors (Weihofen et al., 2002), although it does form higher order 
oligomers (Nyborg et al., 2004b;Nyborg et al., 2006;Miyashita et al., 2011). SPP’s 
simpler structure fits its function as a processor of signal peptides in the membrane, 
which may not require the same extent of regulation as γ-secretase. Below I discuss 
each essential γ-secretase subunit individually, paying particular attention to its role in 
regulating activity.  
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Figure 1.4. The γ-secretase complex is formed by the sequential assembly of Aph1, 
nicastrin (Nct), presenilin (PS), and Pen2. First, Aph1 and Nct come together to 
form the scaffold. Next, PS-FL is incorporated. Last, Pen2 is recruited and PS-FL is 
endoproteolysed into PS-NTF/CTF, activating the enzyme. Nct, a heavily glycosylated 
single-pass transmembrane protein, plays a role in scaffolding, enzyme stabilization, 
substrate recognition, and trafficking. Nct’s amino acids 312-340 are important for 
substrate recognition and deletion of these residues reduces γ-secretase activity and 
Nct’s interaction with APP and Notch. Furthermore, mutation of Nct’s C213 and C230 
leads to different impact on processing of APP and Notch, underscoring Nct’s role in 
substrate selectivity. Aph1, a 7-pass transmembrane protein with 3 human isoforms, is 
crucial for scaffolding and stability, and may have an additional role in determining 
length of Aβ species produced depending on which isoform is incorporated into the γ-
secretase complex. The GXXXG motif in Aph1 is critical for γ-secretase complex 
assembly. PS, a 9-pass transmembrane protein with 2 isoforms, is the catalytic subunit 
of γ-secretase, and PS-FL is a zymogen that must be endoproteolysed into PS-
NTF/CTF to be enzymatically active. Mutations in PS1 and PS2-encoding genes 
account for the majority of genetic mutations leading to Familial Alzheimer’s disease. 
Pen2, a 3-pass transmembrane protein, is required for PS endoproteolysis and γ-
secretase activation, but also may play an endoproteolysis-independent role in γ-
secretase regulation. Active γ-secretase constitutes a small percentage of total γ-
secretase and resides primarily in the plasma membrane. 
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Presenilin 
PS1 and its less abundant isoform PS2, are ~50 kDa multipass transmembrane proteins 
that contain the catalytic core of the γ-secretase complex. These proteins were 
implicated in γ-secretase function when knock-out of PS1 resulted in severely reduced 
γ-secretase activity (De Strooper et al., 1998).  For a long time it was unclear whether 
PS contains the active site of γ-secretase or is a chaperone involved in γ-secretase 
activity or colocalization to substrate. Several seminal studies indicated that PS is 
indeed the catalytic subunit of γ-secretase. First, mutation of the two conserved 
aspartates in both PS1 (Wolfe et al., 1999) and PS2 (Steiner et al., 1999a) significantly 
reduced Aβ production, suggesting that the aspartates are catalytic or essential 
residues for γ-secretase activity. Second, aspartyl protease transition-state analogues 
were shown to directly label and inhibit γ-secretase activity through covalent binding 
to PS, providing compelling evidence for PS as the catalytic core of γ-secretase (Esler 
et al., 2000;Li et al., 2000b). Finally, recombinant PS reconstituted into 
proteoliposomes was shown to be catalytically active even in the absence of other γ-
secretase subunits (in contrast to cellular activity which requires all four subunits), 
providing conclusive evidence for PS’s role as the catalytic subunit of γ-secretase 
(Ahn et al., 2010).  
PS is synthesized as a full length (FL) protein but PS-FL is unstable and is quickly 
either endoproteolysed or degraded (Ratovitski et al., 1997;Thinakaran et al., 
1997;Zhang et al., 1998). Endoproteolysis, a process required for γ-secretase 
activation, results in the formation of PS1-NTF/CTF, which remain associated as a 
stable heterodimer (Podlisny et al., 1997). In fact, the requirement for endoproteolysis 
is an onerous one to meet, as evidenced by the fact that in cells it is dependent on the 
assembly of all four subunits. Furthermore, the ability of FAD mutant PS1∆E9 
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(Thinakaran et al., 1996) to be constitutively active despite its inability to be 
endoproteolysed suggests that evolution has found a way to increase enzymatic 
activity by circumnavigating an important requirement. A parallel can again be drawn 
to the PS-like enzyme SPP, which is not endoproteolysed and is active in its FL form, 
suggesting a simpler form of regulation. The exact molecular mechanism of γ-
secretase endoproteolysis remains unclear, but one approach to study it is through the 
use of active-site directed probes (Gertsik et al., 2014a).   
As mentioned previously, the formation of an active complex is only the first hurdle in 
regulating γ-secretase activity in the cell. An added layer of regulation resides in the 
choice to form PS1 versus PS2-containing complexes. Different PS variants play 
different, albeit overlapping, roles as evidenced by genetic knock out studies (De 
Strooper et al., 1998;Herreman et al., 1999). Later biochemical studies showed  that 
PS1 complexes display a much higher activity than PS2 complexes for a truncated 
APP substrate (Lai et al., 2003). 
PS1 is not only the more active of the two isoforms, but also may be the more 
amyloidogenic. A reconstitution study in which four γ-secretase isoforms (PS1–aph-1a, 
PS1–aph-1b, PS2–aph-1a, PS2–aph-1b) were analyzed showed that PS1 complexes 
form more aggregation-prone Aβ42 (relative to Aβ40) compared to PS2 complexes 
(Lee et al., 2011). This provides further evidence that the 67% homologous PS 
isoforms may have different cleavage-site preferences. It would be interesting to 
investigate whether the PS isoforms also have different substrate preferences. For 
example, do PS1/PS2 complexes differentially cleave APP/Notch? The decision to 
form PS1 versus PS2 complexes probably determines not only “how much” but also 
“what” is cleaved.  
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Pen2 
Presenilin enhancer 2 (Pen2), a ~10 kDa protein with three TMDs (Bai et al., 2015b), 
was discovered as a gene product that can interfere with PS activity in a genetic study 
involving C. elegans (Francis et al., 2002). Pen2 is required for endoproteolysis of PS-
FL into PS-NTF/CTF and for γ-secretase activity. The following evidence supports 
that Pen2 is indispensable for endoproteolysis of PS: first, knock-down of Pen2 by 
RNAi resulted in a decrease of PS1-NTF/CTF and a stabilization of the PS1 
holoprotein in the Nct-Aph1 complex, while transient overexpression of Pen2 in Pen2 
deficient cells led to the recovery of PS fragments (Takasugi et al., 2003). Second, 
coincorporation of recombinant PS1 and Pen2 in liposomes showed Pen2 to be 
necessary and sufficient for endoproteolysis of PS1 (Ahn et al., 2010). Pen2 is also 
required for γ-secretase activity: Pen2 knockdown in mammalian cells resulted not 
only in an accumulation of the PS1 holoprotein, but also in a drastic decrease in γ-
secretase activity (Takasugi et al., 2003). Pen2-/- mouse embryos exhibited a Notch-
deficiency phenotype and Pen2-/- MEFs displayed no γ-secretase activity toward APP 
processing (Bammens et al., 2011). Furthermore, overexpression of human Pen2 in 
Pen2 deficient mice recapitulated AD-like symptoms such as increase in Aβ42, 
behavioral dysfunctions, and feeding defects, underscoring the importance of Pen2 in 
γ-secretase activity and AD pathogenesis (Nam et al., 2011). 
The roles of Pen2 in PS endoproteolysis and γ-secretase activity raised the question – 
is Pen2 necessary for γ-secretase activity per se, or is Pen2-inspired endoproteolysis of 
PS the only requirement for activity? To answer this question the catalytically active 
PS1∆E9 endoproteolysis deficient mutant was expressed in Pen2-/- MEFs and found to 
have no activity, suggesting that Pen-2 is required for γ-secretase activity per se, and 
not just for endoproteolysis of PS (Bammens et al., 2011). This implies that Pen2 
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regulates γ-secretase on multiple levels. We already discussed that Pen2 dictates 
activity, as PS-FL is a zymogen that relies on Pen2-dependent endoproteolysis. This 
type of regulation is close to being an “on” switch, since lack of WT PS 
endoproteolysis precludes γ-secretase activity. However, Pen2 is also capable of more 
subtle regulation in which it modulates the composition of the γ-secretase complex: 
overexpression of Pen2 shifted the equilibrium from PS1 containing complexes to PS2 
containing complexes and increased the Aβ42:Aβ40 ratio (Placanica et al., 2009a). 
Clearly, Pen2 regulates γ-secretase through a variety of mechanisms, not the least of 
which are endoproteolysis of PS and complex assembly.   
Nicastrin 
In the search for cofactors required for γ-secretase activity, Nct, a type I 
transmembrane glycoprotein, was the first to be discovered through 
coimmunoprecipitation with PS1-directed antibody (Yu et al., 2000). A 1.95 Å-
resolution crystal structure of Nct from an amoeboid eukaryote Dictyostelium 
purpureum has been solved (Xie et al., 2014). Four hydrophilic residues in the 
proximal one third of the N-terminal portion of the Nct TMD are critical for 
interaction between Nct and the rest of the γ-secretase complex (Capell et al., 2003). 
Nct interacts initially with Aph1, followed by the incorporation of PS and Pen2 
(LaVoie et al., 2003).  Not only does Nct, together with Aph1, provide a scaffold for 
the γ-secretase complex, but it also may recognize γ-secretase substrates by binding to 
their amino termini. Particularly, Nct’s ectodomain has been shown to bind the 
extracellular regions of APP and Notch after they undergo ectodomain shedding, with 
Nct’s residues 312-340, and especially Glu333, being most important for substrate 
recognition (Shah et al., 2005). This finding branded Nct as the substrate-recruiting 
subunit of γ-secretase. Further confirmation came from work with anti-Nct antibodies: 
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the monoclonal antibody A5226A binds the extracellular domain of Nct causing both 
a disruption in Nct binding to Notch-based substrate (N100) and a decrease in γ-
secretase activity (Hayashi et al., 2011). Additionally, the use of synthetic antibodies 
showed that a certain structured region in Nct, homologous to the TPR domain 
involved in peptide recognition, is critical for substrate binding (Zhang et al., 2012). 
However, several studies had called the “substrate-binding” capacity of Nct into 
question: mutation of mouse Nct-Glu332 (equivalent to human Glu333) to alanine or 
glutamine was reported to hinder assembly of the γ-secretase complex but not its 
specific activity, suggesting that substrate recognition/binding was not affected 
(Chavez-Gutierrez et al., 2008). Furthermore, Nct-independent, L-685,458 specific, γ-
secretase activity has since been detected in two separate MEF lines, suggesting that 
Nct is in fact not required for substrate recognition (Zhao et al., 2010). These results 
support Nct’s role in complex assembly and maturation, but not substrate recognition. 
A subsequent study reexamined the role of Nct and Glu333 in substrate recognition, 
overturning the previous finding and suggesting once again that Nct is indeed involved 
in substrate binding (Dries et al., 2009).  
While Nct’s role as the substrate-binding subunit of γ-secretase may be controversial, 
its importance in γ-secretase regulation is uncontested: mutation of two conserved 
cysteine residues to serine (C213S and C230S) in Nct’s ectodomain resulted in 
differential γ-secretase processing of APP and Notch in MEF cells lacking endogenous 
Nct. In particular, APP processing was reduced compared to Notch, suggesting that 
Nct plays a role in substrate selectivity, although the exact mechanism was not 
identified (Pamren et al., 2011). Furthermore, synthetic anti-Nct antibodies were 
shown to impact substrate selectivity by changing γ-secretase sub-cellular localization 
(Zhang et al., 2014). Quite possibly Nct regulates γ-secretase activity, and particularly 
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substrate selectivity, through a variety of mechanisms including direct substrate 
binding, complex formation/stabilization, maturation, and trafficking. 
Aph1  
Aph1, a ~29 kDa protein with seven TMDs, was discovered in the same genetic screen 
as Pen2 (Francis et al., 2002). The GXXXG motif of Aph1’s TMD4 is crucial for 
assembly into the γ-secretase complex as it plays a major role in intramembrane helix-
helix interactions. Mutation of Gly123 and Gly122 to aspartic acid in C. elegans and 
humans, respectively, results in a loss-of-function phenotype (LOF). The C. elegans 
LOF phenotype gave Aph1 its name: anterior-pharynx-defective (Goutte et al., 2002). 
In mammals, mutation of Gly122 to aspartic acid renders Aph1 incapable of 
associating with the γ-secretase complex, thereby leading to deficiency in Notch 
cleavage (Lee et al., 2004).  
Humans have two Aph1 genes that give rise to three versions of the Aph1 protein 
(Aph1aS, Aph1aL, Aph1b) due to alternative splicing of the Aph1a gene (Shirotani et 
al., 2004). Rodents have an additional isoform, Aph1c, which is a duplication of the 
Aph1b gene. Aph1 isoforms have been reported to differ in their production of longer 
and shorter Aβ peptides. Particularly, when Aph1a, Aph1b, and Aph1c were 
individually reintroduced into an Aph1-a-/-b-/-c-/- mouse,  Aph1a rescue of γ-secretase 
activity resulted in production of shorter Aβ peptides while Aph1b and Aph1c rescue 
led to formation of longer Aβ species. A potential mechanism for this variability may 
stem from the structural changes evident in PS upon binding to one or the other Aph 
isoform: fluorescence lifetime imaging microscopy showed that PS may adopt a more 
closed conformation upon binding to Aph1b compared to its more open conformation 
when in complex with Aph1a (Serneels et al., 2009). This data implies that the choice 
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to incorporate one Aph1 isoform over another can have a profound impact on Aβ 
production and plaque formation.  
γ-Secretase is regulated by modulatory proteins 
γ-Secretase is regulated not only by its four essential subunits, but also by other 
pathways and proteins, many of which have been identified through LCMS analysis 
(Teranishi et al., 2010;Frykman et al., 2012;Teranishi et al., 2012). However, it is 
unclear whether most of these putative γ-secretase-interacting partners actually bind 
the active complex and impact γ-secretase activity. Two γ-secretase-interacting 
partners, GSAP (He et al., 2010;Chu et al., 2014;Zhu et al., 2014) and Hif-1α (Villa et 
al., 2014), have been reproducibly shown to bind active γ-secretase and modulate γ-
secretase activity, rendering them both biologically interesting and potentially 
clinically relevant.  
Implications of γ-secretase regulation  
γ-Secretase is regulated at many levels, including but not limited to regulation by 
“essential” subunits, complex formation, “nonessential” subunits, substrates, and lipid 
composition (Holmes et al., 2012;Walter and van Echten-Deckert, 2013). Although 
the importance of PS in γ-secretase activity is well established, it appears that the other 
essential subunits also notably contribute to regulating activity and substrate 
specificity beyond just their roles in complex assembly. Furthermore, nonessential 
subunits like GSAP and Hif-1α fine-tune modulation of the already stringently-
regulated enzyme, thereby presenting potential therapeutic opportunities for 
modulating γ-secretase activity without the mechanism-based toxicities that result 
from γ-secretase inhibition (i.e. GSIs).  The multifaceted levels of γ-secretase 
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regulation that are now emerging may improve our ability to develop targeted 
therapies for AD and cancer. 
1.5 γ-Secretase inhibitors (GSIs) (Hur et al., 2016) 
Small molecule inhibition of γ-secretase was explored as a potential therapy for AD. γ-
Secretase inhibitors (GSIs) are intended to block γ-secretase cleavage of APP, thereby 
lowering the amount of toxic Aβ produced and slowing neurodegeneration. However, 
these GSIs also block γ-secretase cleavage of other substrates, including the critical 
signaling molecule Notch. A wide range of GSIs have been tested in animals and 
humans, but none have successfully passed clinical trials due to toxicity. A deeper 
understanding of γ-secretase structure and function would help to develop safe and 
effective γ-secretase-based therapies. 
GSIs have extensively been developed as molecular probes and therapeutic agents 
(Josien, 2002;Wolfe, 2012;Golde et al., 2013).  Distinct classes of small molecules 
that target γ-secretase have been reported (Josien, 2002;Wolfe, 2012;Crump et al., 
2013;Golde et al., 2013). Complete inhibition of γ-secretase, as achieved by 
nonselective GSIs, abolishes all γ-secretase activity so that there is a decrease in Aβ 
production and Notch signaling.  "Notch-sparing" GSIs, on the other hand, are 
intended to inhibit Aβ production while leaving some Notch signaling intact (Kreft et 
al., 2008;Mayer et al., 2008).     
Active site-directed GSIs   
Wolfe et al. found that a substrate-based difluoro ketone peptidomimetic compound 
(IC50 = 13 ± 5 μM) inhibited γ-secretase activity in APP-expressing cells (Wolfe et al., 
1998). Shearman et al. reported a potent GSI, L458, which contains a hydroxyethylene 
dipeptide isostere directed to the active site of aspartyl proteases (Shearman et al., 
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2000) (Figure 1.5A). Active site-directed small molecule inhibitors have been 
developed as activity-based probes for identification, localization, and isolation of γ-
secretase and detection of conformational changes within the active site (Li et al., 
2000a;Li et al., 2000b;Beher et al., 2003;Kimberly et al., 2003;Chun et al., 
2004;Tarassishin et al., 2004;Vetrivel et al., 2007;Vetrivel et al., 2008;Placanica et al., 
2009a;Placanica et al., 2009b;Shelton et al., 2009;Yang et al., 2009;Placanica et al., 
2010;Teranishi et al., 2010;Tian et al., 2010a;Crump et al., 2011;Chau et al., 
2012;Gertsik et al., 2015). These probes interact with the PS-NTF/PS-CTF 
heterodimer, but not with PS-FL (Li et al., 2000b;Ahn et al., 2010).  
First-generation GSIs  
Compound E, DAPT, and LY-411,575 are early first-generation GSIs that continue to 
be used for investigation of γ-secretase (Figure 1.5A). Compound E (IC50 = 300 pM) 
was shown to inhibit Aβ production by binding to PS1 and PS2 (Seiffert et al., 2000). 
DAPT (IC50 = 20 nM) was one of the first compounds to show reduction of Aβ in vivo 
(Dovey et al., 2001). When DAPT was orally administered to PDAPP mice 
(harbouring human APP with the ‘Indiana’ mutation [V717F]), brain Aβ levels 
decreased in a dose-dependent manner and APP-CTFs accumulated (Dovey et al., 
2001). Similarly, DAPT decreased Aβ levels in the plasma and CSF of Tg2576 mice 
(harbouring human APP with the ‘Swedish’ mutation) (Lanz et al., 2003). 
Administration of LY-411,575 (IC50 = 30 pM) for 15 days in a murine model of AD 
also led to a reduction in Aβ levels (Wong et al., 2004).  However, side effects on 
lymphocyte development and the intestine were observed due to the inhibition of 
Notch signaling by this GSI (Wong et al., 2004). 
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Clinical GSIs for AD 
Nonselective GSIs 
LY450139 (semagacestat, Eli Lilly) is a potent GSI that pan-inhibits γ-secretase 
cleavage of its substrates and was the first GSI to enter phase 3 clinical trials (Figure 
1.5B). The most surprising outcome of the clinical trial of semagacestat was the 
worsening of memory in patients (Doody et al., 2013). The other major adverse effect 
of the trial was the increased risk of skin cancer, which likely resulted from inhibition 
of Notch signaling (Xia et al., 2001;Nicolas et al., 2003). While the Notch-associated 
side effects are somewhat understood, the mechanism of cognitive decline is elusive. 
“Notch-Sparing” GSIs 
GSI-953 (begacestat, Wyeth [now Pfizer]) is a thiophene sulfonamide GSI (Martone et 
al., 2009) (Figure 1.5B). It is 16 times more potent for inhibition of APP cleavage 
versus Notch cleavage in the assays used and was optimized for improved stability in 
humans (t1/2 > 90 min) compared to other Wyeth compounds (Martone et al., 
2009;Hopkins, 2012). Begacestat was reported to decrease plasma, brain, and CSF Aβ 
levels in Tg2576 mice overexpressing APP and also reduce plasma Aβ levels in a 
dose-dependent manner in healthy humans (Martone et al., 2009). While begacestat 
appeared to have a higher selectivity for APP over Notch than semagacestat, it was 
discontinued in the phase 1 trial in 2010 for unknown reasons. 
BMS-708163 (avagacestat, Bristol-Myers Squibb) is a sulfonamide-based GSI that has 
a preference for inhibition of APP processing over Notch processing (Gillman et al., 
2010)(Figure 1.5B). Initially, avagacestat was reported to have 193-fold selectivity for 
APP over Notch in cell culture (Gillman et al., 2010). Although the major adverse 
effects of the avagacestat phase 2 trial were gastrointestinal and dermatologic 
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complications, which probably stemmed from Notch inhibition, the 100 mg and 125 
mg dose arms also led to a trend for cognitive worsening (Coric et al., 2012), 
suggesting that avagacestat may share a common mechanism of toxicity with 
semagacestat. While avagacestat was initially reported as a Notch-sparing inhibitor 
(Gillman et al., 2010), two groups were unable to reproduce this result using different 
assay formats (Chavez-Gutierrez et al., 2012;Crump et al., 2012b). Therefore, the 
toxicity can be partially attributed to the inhibition of Notch signaling (Chavez-
Gutierrez et al., 2012;Crump et al., 2012b;De Strooper, 2014). A recent study 
suggested that the worsening in cognition by treatment with semagacestat and 
avagacestat could be due to the accumulation of APP-CTF in the presynaptic terminals 
of the hippocampus (Mitani et al., 2012). 
1.6 γ-Secretase modulators (GSMs) 
GSMs are compounds that have numerous attributes favorable for AD treatment. 
Specifically, GSMs reduce amyloidogenic Aβ42, do not affect quantity of total Aβ, 
and do not inhibit Notch signaling. What makes GSMs different from GSIs is their 
ability to keep total Aβ constant, by raising amounts of shorter Aβ species, and their 
ability to interfere with APP processing without interfering with Notch processing. By 
maintaining total Aβ constant, these compounds prevent the accumulation of the toxic 
βCTF, and by maintaining Notch processing, GSMs allow for normal cell signaling to 
continue in pathways unrelated to Aβ formation.  
First generation GSMs 
GSMs were discovered when some NSAIDS, such as ibuprofen, indomethacin, and 
sulindac sulfide, were found to reduce Aβ42 and increase Aβ38 without inhibiting 
Notch1 signaling (Weggen et al., 2001). Moreover, these properties were dissociated 
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from their cyclooxygenase (COX) activity. For the first time it seemed that γ-secretase 
activity could be modulated, not just inhibited, but the low in vitro (Aβ42 IC50 >10 
μM) potency and brain penetration of these compounds precluded them from 
becoming promising clinical candidates (with the exception of R-flurbiprofen which 
made it to phase III trials but did not achieve statistically significant outcomes (Green 
et al., 2009)).  
Second generation GSMs 
Second generation GSMs, which are either NSAID-derived carboxylic acids, non-
NSAID-derived heterocyclic GSMs, or natural product-derived GSMs, were 
developed with the goal of improving potency and brain penetration.  
NSAID-derived heterocyclic GSM: GSM-1 is a piperidine acetic acid GSM that 
increases Aβ38 at the expense of Aβ42 and does not impact Aβ40 and NICD levels. 
When WT and Tg2576 mice were treated with GSM-2 (a piperidine acetic acid), 
LY450139, or BMS-708163, the only compound to recover cognition as shown by the 
Y-maze test was GSM-2 (Mitani et al., 2012). In fact, LY450139 (Figure 1.5B) 
actually impaired cognition in WT mice, suggesting that accumulated β-CTF may be 
toxic and non-selective inhibition of γ-secretase is not a viable AD therapy.  
Non-NSAID-derived heterocyclic GSM: E2012 (Figure 1.5C) is an imidazole 
compound, developed by Eisai, that enhanced Aβ37 and 38 at the expense of Aβ42, 40, 
and 39 (Portelius et al., 2010;Borgegard et al., 2012). It entered phase I clinical trials 
(Nagy et al., 2010), was dropped for an improved version called E2212, and has not 
been heard from since (clinicaltrials.gov identifier NCT01221259).  
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GSM mechanism of action 
How do GSMs reduce Aβ42 without affecting overall Aβ production and Notch 
signaling? Three mechanisms of action were proposed by different groups: 1. GSMs 
bind γ-secretase (Takahashi et al., 2003;Beher et al., 2004;Clarke et al., 2006) 2. 
GSMs bind APP, the substrate of γ-secretase or (Kukar et al., 2008;Botev et al., 2011) 
3. GSMs bind both γ-secretase and APP (Lleo et al., 2004;Uemura et al., 2010). 
However, all of these studies were performed with low potency NSAID GSMs, which 
required compounds in high micromolar concentrations. It was shown that sulindac 
sulfide aggregates above 50 μM (Barrett et al., 2011). As a result of high compound 
concentrations, many of these studies identified unspecific GSM-interacting proteins 
that were mistaken for true targets. The literature filled with contradictory findings and 
most data was difficult to interpret. With the advent of second generation GSMs, the 
search for GSM targets finally began to yield clearer results. Despite their structural 
diversity, all second generation GSMs known to date were shown to bind γ-secretase 
and not APP (Crump et al., 2011;Ebke et al., 2011;Ohki et al., 2011;Jumpertz et al., 
2012;Pozdnyakov et al., 2013). One of the most convincing pieces of evidence for PS 
as the target of GSMs is the finding that a probe form of GSM-1 specifically binds to 
reconstituted PS1ΔE9 in liposomes without substrate (Ahn et al., 2010). Although 
second generation GSMs were all found to target γ-secretase, a series of reciprocal 
labeling experiments showed that GSM binding occurs in different regions of PS 
(Figure 1.5C). Not surprisingly, GSMs have been found to induce conformational 
changes in γ-secretase (Uemura et al., 2010;Crump et al., 2011;Ohki et al., 
2011;Gertsik et al., 2015). 
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Figure 1.5. A. Structures of L458 and first generation GSIs B. Structures of GSIs that 
have advanced into clinical studies for AD. C. Schematic showing that structurally 
diverse GSIs/GSMs bind in different allosteric regions on PS and have an impact on 
the enzyme active site. 
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1.7 Activity-based protein profiling (ABPP) 
ABPP is a chemical proteomic strategy that profiles the activity of enzymes and 
contributes to inhibitor development and functional understanding (Niphakis and 
Cravatt, 2014). ABPP can be used to study the mechanism of catalysis, the mechanism 
of action of other small molecules that target the enzyme of interest, or in conjunction 
with gene disruption to trace biological pathways. ABPP also allows us to become a 
lot more sophisticated in drug development, as we can use the information gleaned 
from activity-based probes’ (ABPs) interaction with the proteome to make compounds 
that are increasingly more specific for our target of interest. ABPP relies on the ability 
of compounds to distinguish between active and inactive forms of an enzyme. ABPs, 
which have been developed for a wide array of enzymes with aspartate, glutamate, 
cysteine, lysine, tyrosine, and serine catalytic residues, consist of a reactive group for 
covalent linkage, a binding group for affinity, and a reporter tag for isolation. We use 
a photoactive benzophenone for covalent linkage, an aspartyl protease active site-
directed transition state peptidomimetic with a hydroxyethylene isostere (L458) (Li et 
al., 2000b) for affinity and a biotin (or clickable alkyne) for isolation. 
1.8 Thesis overview: insights into drug development for AD using chemical 
probes  
While all clinical trials for treating AD with GSIs have failed to date, there is reason to 
believe that a successful Aβ-reducing therapy is around the corner. Recent analyses 
and discussion questioned whether GSIs, such as semagacestat or avagacestat, were 
the best candidates for clinical studies (Chavez-Gutierrez et al., 2012;Crump et al., 
2012b;De Strooper, 2014), and suggested that the failed clinical trials do not 
disqualify γ-secretase as a target for AD drug development (De Strooper, 
2014;Alzforum, 2015;De Strooper and Chavez Gutierrez, 2015). Past failures with 
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GSIs appear to have been a result of suboptimal compound selection and poorly 
designed trials. For example, the once-a-day dosing regimen of semagacestat resulted 
in abrupt inhibition of γ-secretase followed by a rebound in activity and Aβ production. 
This not only led to spikes in Aβ, but also may have interfered severely with Notch 
signaling. A constant, moderate dose treatment may have improved trial results. 
Moreover, both semagacestat and avagacestat are non-selective GSIs that caused 
severe Notch-associated toxicities. As a result, the cognitive worsening observed with 
these compounds may have been a result of making patients very sick. By taking into 
account the lessons we have learned, it will be possible to design efficacious, 
minimally toxic drug candidates to slow or arrest disease progression. In fact, clinical 
investigation of aducanumab (BIIB037) suggests that targeting Aβ is a valid strategy 
for AD drug development (BioGen, 2015).  
To create effective Aβ-reducing therapies, we must delve deeper into disease 
mechanism through a better understanding of the structure and function of γ-secretase 
(De Strooper, 2014;Alzforum, 2015;De Strooper and Chavez Gutierrez, 2015). One 
major challenge lies in obtaining a clearer picture of γ-secretase biology, and in 
particular, the processes by which the zymogen is converted into its active form. In 
this work we developed CBAP-BPyne, a tool to study the process of γ-secretase 
activation. Insights into enzyme endoproteolysis and activation, a set of events about 
which much has been written but little is understood, will not only teach us about the 
basic biology of this protein, but can also inform drug development as we intervene in 
specific enzymatic formation/activation events. An understanding of endoproteolysis 
can shed light on the mechanism by which PS1∆E9, an FAD mutation that is 
endoproteolytically deficient but enzymatically active, causes an accumulation of Aβ 
and subsequent neurodegeneration. Rational drug design will be well served by a 
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recognition for the physiological and pathological processes by which γ-secretase is 
activated. 
Another challenge of AD drug development lies in retaining the physiological activity 
of γ-secretase while decreasing its pathological activity, a feat that can be attained 
through development of selective GSIs or GSMs, compounds that lower formation of 
the toxic Aβ42 without affecting formation of other γ-secretase cleavage products. 
While we and others have developed GSMs that fit this profile and appear to have 
minimal mechanism-based toxicity, we know little about their potential off-target 
effects. Here we extend our understanding of structurally distinct GSMs by 
determining their impact on the active site architecture of an off-target protein, SPP. 
SPP cleaves transmembrane signal peptides after they have been cleaved off the 
protein by signal peptidase (SP) and SPP is required in eukaryotes. The modulation of 
SPP may result in off-target toxicities that need to be thoroughly understood before 
another attempt at GSI/GSM clinical development.  
Yet a third challenge is in obtaining a high resolution understanding of drug-γ-
secretase interaction. Because there is no crystal structure of γ-secretase, we have a 
limited understanding of where GSIs/GSMs bind and how the location of binding 
impacts the modulation profile. Whether the recent high resolution electron 
microscopy (EM) structure of γ-secretase (Bai et al., 2015b) illustrates an active 
enzyme complex is questionable. We have taken the first step toward a structure-
function understanding of GSIs/GSMs and their enzyme target by identifying the 
binding site of BMS-708163, a GSI that was in clinical trials. This work combines 
probe development with the study of γ-secretase biology, the union of which we hope 
brings us another step closer to safe and effective AD therapies.  
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CHAPTER 2 
Development of CBAP-BPyne, a probe for γ-secretase and presenilinase (PSase) 
(Gertsik et al., 2014a) 
2.1 Introduction 
γ-Secretase activity is required for development, as PS1 knock-out mice are embryonic 
lethal (Shen et al., 1997;Wong et al., 1997). Endoproteolysis of PS, or as we will 
interchangeably call it, presenilinase (PSase), is required for γ-secretase activation 
(Figure 2.1). This logically leads to the supposition that PSase is required for 
development. As a result, reports of familial Alzheimer’s disease (FAD) mutations 
that abolish PSase are very surprising. In fact, the existence of an endoproteolytically 
dead PS1 FAD mutant – PS1∆E9, in which amino acids 290-319 are deleted – appears 
to invalidate the above conclusion that PSase is required for development. Deletion of 
the exon 9 encoded peptide loop of PS1, found between transmembrane domains 
(TMDs) 6 and 7 (Laudon et al., 2005), results in an active γ-secretase that does not 
depend on endoproteolysis for its activation.  
 
Figure 2.1. Endoproteolysis of PS1. PS1-FL (full-length) is endoproteolysed by 
PSase in a hydrophobic stretch of the cytoplasmic loop, to form a ~27 kDa NTF and 
~16 kDa CTF. Endoproteolysis and subsequent PS1-NTF/CTF heterodimer formation 
are required for γ-secretase activity, as PS1-FL is a zymogen, activated by 
autocleavage. (D: catalytic Asp residues)  
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Under wild-type (WT) conditions, endoproteolysis and concurrent PS1-NTF/CTF 
fragment formation are required for γ-secretase activity, as full length PS (PS1-FL) is 
a zymogen, activated by autocleavage (Li et al., 2000b;Ahn et al., 2010;Lessard et al., 
2010). PS is synthesized in the ER as a full length, 467 amino acid protein, but PS-FL 
is unstable (T1/2~1 hour) and is quickly either endoproteolysed or degraded (Ratovitski 
et al., 1997;Thinakaran et al., 1997;Zhang et al., 1998). Endoproteolysis occurs 
between amino acids 298 and 299, or 292 and 293, in a hydrophobic stretch of the 
cytoplasmic loop  to form a ~27 kDa amino terminal fragment (NTF) and ~16 kDa 
carboxy terminal fragment (CTF) (Thinakaran et al., 1996;Podlisny et al., 
1997;Steiner et al., 1999b). The two fragments, each of which donates an aspartate 
residue to form the active site (D257 and D385), go on to generate a stable 
heterodimer with a long biological half-life (T1/2~12 hours) (Zhang et al., 1998). 
However, mutations in PS can also activate γ-secretase, as evidenced by PS1∆E9, 
which results in an uncleavable, constitutively active PS1 variant (Thinakaran et al., 
1996). This mutant causes an increase in the Aβ42:Aβ40 ratio and early onset AD 
(Cruts et al., 2012). Mutagenesis studies have further shown that a single M292D 
amino acid substitution is sufficient to form an endoproteolytically deficient and 
catalytically active PS1 (Steiner et al., 1999b). Additional PS FAD mutations that have 
little endoproteolysis but retain γ-secretase activity exist (Godbolt et al., 2004). The 
function of these mutations may be explained by studies that have shown that PS1-FL 
can support γ-secretase activity. For example, a random mutagenesis screen identified 
endoproteolytically deficient PS1 mutants that had increased activity for longer Aβ 
production (Aβ43) (Nakaya et al., 2005). Clearly, endoproteolysis is just one of a 
variety of ways in which the γ-secretase complex can be activated. This is not 
surprising, as we now know that γ-secretase is regulated on many levels by a variety of 
complex formation events and interacting partners (see introduction). Understanding 
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the mechanism of PSase will clarify γ-secretase activation under WT conditions, and 
may also serve as a model for γ-secretase activating mutations in disease conditions.    
γ-Secretase and PSase have much overlap but are not the same 
Before the enzyme responsible for the endoproteolytic cleavage of PS was known, it 
was termed “presenilinase” (PSase). Current evidence suggests that PSase is actually 
PS itself, and endoproteolysis is an autocatalytic cleavage event. This is illustrated by 
the following observations: 1. Mutation of PS’s catalytic aspartate residues not only 
blocks γ-secretase activity, but also PSase activity (Wolfe et al., 1999). 2. Pepstatin A, 
an aspartyl protease inhibitor, suppresses PSase activity, further suggesting that PSase 
is an aspartyl protease (Campbell et al., 2002). 3. PSase is an integral membrane 
protein, as its activity is not lost upon washing membrane vesicles with sodium 
carbonate (Campbell et al., 2002). 4. The coexpression of WT PS1 with PS1 D257A (a 
γ-secretase and PSase deficient mutant) does not restore endoproteolysis of the mutant 
(Brunkan et al., 2005a), indicating that endoproteolysis occurs in cis and is an 
autocatalytic event. 5. An in vitro reconstitution study showed that bimolecular 
interaction of PS1 and Pen2 is necessary and sufficient for PS1 endoproteolysis (Ahn 
et al., 2010). Pen2 is unlikely to be PSase, and is probably required to orient PS in a 
conformation that facilitates autocatalytic cleavage.  
γ-Secretase and PSase are intimately tied, as both are aspartyl proteases (Campbell et 
al., 2003) and PSase is necessary for formation of mature, active γ-secretase under WT 
conditions. However, γ-secretase and PSase are not identical (Figure 2.2). This is 
illustrated by the following observations: 1. Some endoproteolysis deficient PS1 
mutants have γ-secretase activity (PS1∆E9 and M292D), so PSase is not strictly 
required for γ-secretase (Steiner et al., 1999b). 2. Some PS1 mutations, including PS1 
FAD mutations, that alter γ-secretase activity have no effect on PSase (Steiner et al., 
36  
2000;Campbell et al., 2002;Laudon et al., 2004;Brunkan et al., 2005b). 3. The active 
site-directed, peptidomimetic γ-secretase inhibitor L685,458 (L458) binds and inhibits 
γ-secretase without inhibiting PSase (Beher et al., 2001). These findings, summarized 
in Figure 2.2, suggest that while endoproteolysis is required for γ-secretase activity in 
most cases, other activating mechanisms, such as deletions/mutations in PS1, do exist. 
Furthermore, it appears that, given the right tools, γ-secretase and PSase can be 
dissociated and studied separately in order to better understand the mysterious process 
of endoproteolysis.  
Bio-orthogonal probe development – “click” chemistry  
In order to perform activity-based protein profiling (ABPP) we needed an active site-
directed probe that could be covalently crosslinked to target proteins and pulled-down 
for protein isolation. While a biotin moiety could be directly attached to the probe for 
enrichment, this would result in a bulky protrusion that may modulate or attenuate the 
probe’s activity. To avoid this, we took advantage of copper-catalyzed azide-alkyne 
cycloaddition (CuAAC), which is bio-orthogonal to the system in which it is carried 
out, meaning the precursors do not react with biomolecules but do react with each 
other at high efficiency (Rostovtsev et al., 2002;Tornoe et al., 2002). We introduced 
an alkyne into the probe, which can be “clicked” to biotin-azide (or TAMRA-azide) 
after the probe bound target proteins. Next, the protein-probe-biotin complex can be 
pulled-down with streptavidin beads for protein isolation and identification. This 
clickable probe approach facilitates the design of functional probes that can selectively 
label and detect proteins in complex cellular systems with minimal modification to the 
original compound (Crump et al., 2011;Crump et al., 2012a;Crump et al., 
2012b;Pozdnyakov et al., 2013;Gertsik et al., 2014a). 
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Figure 2.2. γ-Secretase and presenilinase (Psase) are not the same. A. Some 
endoproteolysis deficient PS1 mutants have γ-secretase activity (i.e. PS1∆E9), so 
PSase is not strictly required for γ-secretase Left: PS1-FL does not have γ-secretase 
activity. Middle: The FAD mutant PS1ΔE9, which lacks amino acids 290-319 and 
does not undergo endoproteolysis, has γ-secretase activity. Right: PS1-NTF/CTF 
fragments, which form as a result of PS-FL endoproteolysis, have γ-secretase activity. 
B. PS1 FAD mutations with different effects on PSase. Some PS1 mutations, 
including PS1 FAD mutations, that alter γ-secretase activity have no effect on PSase. 
C. The active site-directed, peptidomimetic γ-secretase inhibitor L458 inhibits γ-
secretase but not PSase. Conversely, the aspartyl protease inhibitor pepstatin A 
inhibits both γ-secretase and PSase.  
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How can we separate the highly interdependent but separate activities of γ-secretase 
and PSase? 
Notwithstanding findings that PS possesses γ-secretase and PSase activities, it has 
been a formidable challenge to characterize both activities and understand their 
differences due to their complex interdependence. While many γ-secretase active site-
based inhibitors exist to directly probe γ-secretase, no successful PSase-directed 
probes exist to date. CBAP (Figure 2.3A) is a γ-secretase inhibitor that also causes a 
“pharmacological knock-down” of PS1 NTF/CTF with a concomitant accumulation of 
PS1-FL in the cell (Beher et al., 2001).  However, the mechanism of action of CBAP 
in γ-secretase and PSase remains to be investigated. Here, we have synthesized CBAP-
BPyne, a clickable, photoreactive form of CBAP, as a tool to understand the 
mechanism of PSase (Figure 2.3).  
2.2 Results 
CBAP, a potent γ-secretase inhibitor, is a chimeric compound containing a transition 
state isostere similar to L458 and a benzodiazepine group similar to the GSI 
Compound E (Seiffert et al., 2000). CBAP was found to accumulate PS1-FL with 
concomitant PS1 NTF/CTF fragment depletion in SH-SY5Y cells that were treated for 
7 days (Beher et al., 2001). CBAP offers a unique opportunity for probe development 
and PSase mechanistic studies.  
Synthesis of CBAP-BPyne 
The CBAP intermediate TBS-protected alcohol (4) was synthesized by coupling 
amino benzodiazepinone 3 to carboxylic acid 1 as previously reported (Beher et al., 
2001). To synthesize CBAP-BPyne, we initially investigated the selective removal of 
the NHBoc group from 4, but all conditions examined resulted in poor product 
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formation where removal of the silyl and Boc protecting groups occurred at 
competitive rates. It was determined that selective Boc group removal or one-pot 
global deprotection strategies were not viable to produce the CBAP-BPyne in 
sufficient yields and purity. CBAP-BPyne was ultimately synthesized by removing the 
silyl protecting group in 4 with TBAF to yield CBAP followed by a rapid deprotection 
of the NHBoc group at 0 °C in dilute TFA to produce the fully deprotected scaffold. 
The crude amino alcohol was then immediately coupled with the NHS ester of 
propargyl benzophenone 2 to afford CBAP-BPyne ‡ (van Scherpenzeel et al., 2009) 
(Figure 2.3B). 
 
 
 
 
 
 
40  
 
Figure 2.3. A. Structures of L458, CBAP, and CBAP-BPyne. Red: clickable alkyne; 
blue: crosslinkable benzophenone B. Reagents and conditions for synthesis of CBAP-
BPyne. a) 1, HATU, DIPEA, DMF, 24 h, RT, 83%; b) TBAF, THF, 6 h, RT, 84%; c) 
TFA, CH2Cl2, 5 min, 0 °C; d) 2, DIPEA, DMF, 18 h, 79%. 
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CBAP-BPyne inhibits both γ-secretase and PSase  
CBAP-BPyne contains a photophore for photoaffinity labeling and an alkyne for 
CuAAC. First, using our in vitro γ-secretase activity assay with recombinant APP and 
Notch1 substrates (Placanica et al., 2009b;Shelton et al., 2009;Tian et al., 2010a;Chau 
et al., 2012;Chau et al., 2013), we determined that both CBAP and CBAP-BPyne are 
equipotent γ-secretase inhibitors. Specifically, both compounds potently inhibit γ-
secretase activity for the production of Aβ40 and Notch1-NICD (Figure 2.4A, left). 
Next, we examined CBAP and CBAP-BPyne’s cellular activity in inhibiting PS1 
processing. HeLa cells were treated for four days in a 12-well plate with CBAP, 
CBAP-BPyne, L458, or vehicle control at concentrations of 1, 3, or 10 μM and lysates 
were Western blotted for PS1-NTF. CBAP and CBAP-BPyne caused a much greater 
accumulation of PS1-FL at the expense of PS1-NTF/CTF than did L458 (Figure 2.4B 
for PS1-NTF and data not shown for PS1-CTF). We saw a very similar effect when 
SH-SY5Y cells were treated with 10 μM of all the same compounds for seven days 
and Western blotted, probing with anti PS1-NTF antibody (Figure 2.4C). This 
indicates that CBAP and CBAP-BPyne are capable of inhibiting PSase activity, while 
L458 has little effect on PSase activity under these conditions. CBAP is a more potent 
PSase inhibitor than CBAP-BPyne as seen by the nearly complete depletion of PS1-
NTF in CBAP treated cells compared to the incomplete PS1-NTF depletion in CBAP-
BPyne treated cells (Figure 2.4B, C). This effect is not due to a difference in the 
ability of the compounds to permeate the cell membrane because CBAP and CBAP-
BPyne were equipotent in a cell-based γ-secretase activity assay in CHO-APP cells 
(Aβ42 IC50 = 28 nM and 20 nM, for CBAP and CBAP-BPyne, respectively) and in 
N2A-APP cells (Aβ40 IC50 = 95 nM, 167 nM, and 330 nM for CBAP, CBAP-BPyne, 
and L458, respectively) (Figure 2.4A, right). The ~2X difference between the Aβ40 
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IC50s of CBAP and CBAP-BPyne is negligible as Aβ40 IC50 for L458 was 330 nM, 
suggesting the differences are due to natural variation in the cell-based activity assay.  
 
Figure 2.4. A. In vitro and cell-based inhibitory potency (IC50) of CBAP and CBAP-
BPyne. B. HeLa cells were treated with 1, 3, and 10 μM of CBAP, CBAP-BPyne, and 
L458, or vehicle control (DMSO), for 4 days. Protein concentration was determined 
and same amount of cell lysate (15 μg) was run on SDS-PAGE. Western blot analysis 
was performed with an anti PS1-NTF antibody. C. SH-SY5Y cells were treated with 
10 μM of various compounds for 7 days and Western blotted as in B.  
CBAP-BPyne labels γ-secretase 
We determined that CBAP-BPyne is a functional probe, as photoaffinity labeling 
followed by CuAAC, biotin pull-down, and Western blot showed that CBAP-BPyne 
specifically labels PS1-NTF (Figure 2.5A, left). CBAP-BPyne was also found to label 
signal peptide peptidase (SPP), a protein structurally similar to PS (Figure 2.5A, right). 
Photoaffinity labeling studies followed by CuAAC with TAMRA-azide confirmed the 
specific labeling of PS1-NTF and SPP, and showed that CBAP-BPyne binds 
additional proteins, although PS1-NTF is the primary target (Figure 2.5B). The 
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additional unidentified proteins that are specifically labeled (denoted with a star) may 
play a role in endoproteolysis and should be studied further for their identity and 
function. Whether bands that migrated in the range of high molecular weight represent 
aggregated PS1-NTF, SPP, or novel proteins also remains to be investigated. 
 
 
Figure 2.5. HeLa membranes were photolabeled with CBAP-BPyne (20 nM) in the 
presence (+) or absence (-) of CBAP (2 μM), followed by click chemistry with: A. 
biotin-azide, streptavidin pull-down, and Western blot analysis with either anti PS1-
NTF (left), or SPP (right) antibody or B. TAMRA-azide, in-gel fluorescence (left) and 
Coomassie blue gel staining (right). Stars represent unidentified proteins that are 
specifically labeled by CBAP-BPyne.  
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CBAP-BPyne does not label PS1-FL 
We hypothesized that PS-NTF/CTF has γ-secretase activity and PS-FL has PSase 
activity. As a result, we expected that CBAP inhibits γ-secretase by binding to PS-
NTF/CTF and that it inhibits PSase by binding to PS-FL. In the previous section, 
through the use of CBAP-BPyne, we confirmed that CBAP does in fact label γ-
secretase. In this section we set out to determine whether it also binds PS-FL. 
We could not look for PS1-FL labeling in HeLa cell membrane because PS1-FL that is 
not endoproteolysed is rapidly degraded, so HeLa has no detectable PS1-FL. To 
circumvent this problem, we looked for labeling of PS1-FL in ANP24 and ANPP8 cell 
membranes, which are HEK293 overexpressing cells with high levels of PS1-FL (Kim 
et al., 2003) (Figure 2.6A). ANP24 cells have little endoproteolysis as they 
overexpress all γ-secretase components except Pen2. As a result, these cells have more 
PS-FL than PS-NTF/CTF. ANPP8 cells overexpress all four γ-secretase components. 
As a result, these cells have more PS1-NTF/CTF than PS-FL. Both cell lines have 
ample PS1-FL. First, we photolabeled both ANP24 and ANPP8 cell membranes with 
various concentrations of CBAP-BPyne (20 nM–500 nM, only 500 nM labeling of 
ANP24 shown here) (Figure 2.6B). While we found robust PS1-NTF labeling, we 
were unable to detect any specific PS1-FL labeling. We considered the possibility that 
additional factors may be required for successful CBAP-BPyne labeling of PS1-FL 
and performed live-cell labeling experiments in which CHAPSO permeabilized 
ANP24 and ANPP8 cells were photolabeled with 500 nM CBAP-BPyne in the 
presence (+) or absence (-) of 10 μM CBAP (Figure 2.6C). Again, no PS1-FL labeling 
was detected but PS1-NTF was clearly labeled. PS1-NTF in ANPP8 is more robustly 
labeled than that in ANP24 because there is more active γ-secretase in ANPP8, which 
expresses all four components of γ-secretase, than there is in ANP24, which does not 
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have Pen2. We hypothesized that the γ-secretase complex in the overexpressing cells 
may not be in the proper conformation for labeling by CBAP-BPyne due to artifacts of 
overexpression. To test this, we treated SH-SY5Y cells, which have endogenous levels 
of γ-secretase, with 1 μM CBAP-BPyne for 48 hours in order to accumulate PS1-FL, 
switched the cells into new media with fresh 1 μM CBAP-BPyne, and 
photocrosslinked (Figure 2.6D). Switching the cells into media with fresh compound 
was critical because when we removed the media and did not add any fresh compound, 
we did not see any PS1-NTF labeling. This is probably because CBAP-BPyne 
degraded over the course of the incubation at 37 ˚C. Again, we observed labeling of 
PS1-NTF but not PS1-FL. These and other experiments convinced us that CBAP-
BPyne is not labeling PS1-FL.  
CBAP-BPyne is not acting through the proteasome pathway 
Since CBAP-BPyne did not label PS1-FL, we recognized that there is a possibility that 
CBAP accumulates PS1-FL through some other mechanism, such as proteasome 
inhibition. To rule this out, we treated SH-SY5Y cells either with 1 μM CBAP-BPyne 
for 48 hours, 20 μM MG132 (a proteasome inhibitor) for 2 hours, or both (Figure 
2.6E). Treatment of SH-SY5Y cells with MG132 did not accumulate PS1-FL, 
suggesting that the mechanism of PS1-FL accumulation is not through inhibition of 
the proteasome. 
CBAP-BPyne does not impact the levels of other γ-secretase subunits  
Another potential pathway through which CBAP may be accumulating PS1-FL is by 
downregulating γ-secretase subunits other than PS. For example, if CBAP 
downregulates Pen2, a protein required for endoproteolysis, then cleavage of PS-FL 
cannot occur. Similarly, the downregulation of either Nct or Aph1 would impair 
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complex formation and inhibit endoproteolysis, which occurs exclusively in mature 
complexes that have all four subunits. We checked the levels of Nct and Pen2 in SH-
SY5Y cells treated for four days with 10 μM CBAP, L458, and vehicle control (Figure 
2.6F). The levels of these proteins were not changed compared to DMSO control, 
illustrating that CBAP does not accumulate PS1-FL through downregulation of these 
γ-secretase subunits. This was confirmed by the finding that CBAP-BPyne does not 
label PS1-CTF or any of the other three subunits (Nct, Pen2, Aph1) of γ-secretase 
(Figure 2.6G). Specifically, when HeLa membrane was photolabeled with 20 nM 
CBAP-BPyne +/- 2 μM CBAP there was no labeling of Pen2, Aph1, or Nct especially 
when compared to positive control labeling by GSI-877 (163-BP3), a probe that pulls-
down all components of the γ-secretase complex. To confirm that CBAP does not 
target Pen2, we used a higher concentration of compound for labeling of ANPP8 
membrane: ANPP8 membrane was photolabeled with 500 nM CBAP-BPyne, 
followed by click chemistry and Western blot for Pen2 (data not shown). Again, there 
was no Pen2 labeling. Similarly, when ANP24 membrane was photolabeled with 20 
nM CBAP-BPyne +/- 2 μM CBAP there was no labeling of PS1-CTF, especially when 
compared to positive control labeling by GSI-256, which is an active site-directed 
probe that labels both PS1-NTF and PS1-CTF.  
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Figure 2.6. A. Relative levels of PS1-NTF/CTF and PS1-FL in ANP24 (3 γ-secretase 
subunits) and ANPP8 (4 γ-secretase subunits) cell lysate shown in duplicate. B. 
ANP24 membrane (600 μg) or C. live ANP24 and ANPP8 cells were photolabeled 
with CBAP-Bpyne (500 nM) in the presence (+) or absence (-) of CBAP (10 μM), 
followed by click chemistry and Western blot, probing for PS. Input=5 ug ANP24 
membrane. D. SH-SY5Y cells were treated with 1 uM CBAP-BPyne for 48 hours and 
crosslinked with fresh 1 μM CBAP-BPyne followed by click chemistry and Western 
blot, probing for PS. Input=lysate from SH-SY5Y cells that were treated with CBAP-
BPyne. E. SH-SY5Y cells were treated with 1 uM CBAP-Bpyne (48 hrs), 20 μM 
MG132 (2 hrs), or both. Cells were lysed and Western blotted. Input=5 μg ANP24 
membrane. F. SH-SY5Y cells treated for 4 days with 10 μM indicated compound, 
lysed, and Western blotted for Pen2 and Nct. Experiment shown in duplicate. G. Top 
panel: structures of GSI-877 and GSI-256. Bottom left panel: HeLa membrane 
photolabeled with 20 nM GSI-877 +/- 2 μM GSI-495 or 20 nM CBAP-BPyne +/- 2 
μM CBAP, followed by click chemistry and Western blot for Pen2, Aph1, or Nct. 
Bottom right panel: ANP24 membrane photolabeled with 20 nM GSI-256 +/- 2 μM 
L458 or 20 nM CBAP-BPyne +/- 2 μM CBAP, followed by click chemistry and 
Western blot for PS1-CTF. 
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Figure 2.6 
 
 
49  
2.3 Conclusion and Discussion 
CBAP-BPyne is the first clickable, photoreactive probe that inhibits both γ-secretase 
and PSase activities (Figure 2.7A). However, CBAP-BPyne labels γ-secretase but not 
PSase. This may be because 1. CBAP-BPyne does not bind PS1-FL or 2. CBAP-
BPyne binds PS1-FL, but the crosslinking efficiency is low. If scenario one is correct 
and CBAP-BPyne has a target other than PS1-FL, then large scale pull-down, LC-MS, 
and validation studies can identify this protein and confirm its role in endoproteolysis. 
As the TAMRA gel illustrates, CBAP-BPyne certainly has targets other than PS, but 
whether these proteins play a role in endoproteolysis remains unknown. We confirmed 
that these candidate proteins are not Pen2, Aph1, PS1-CTF or Nct. This begs the 
question, can another, yet unknown protein be playing a role in endoproteolysis? 
While unlikely, this possibility is worth exploring. Scenario two seems more plausible 
because our data shows that the potency of CBAP-BPyne for γ-secretase inhibition is 
much higher than it is for PSase inhibition. Consequently, the probe used in labeling 
experiments may be binding PS1-NTF tightly without having a chance to significantly 
interact with and bind PS1-FL. If this is the case, then SAR can help improve the 
efficiency of probe binding to PS1-FL. We have previously found that the location of 
the crosslinkable moiety on a probe is critical for efficient labeling. Particularly, steric 
issues and amino acid/benzophenone distances play a major role in crosslinking 
efficiency. This is illustrated by the observation that all four of our L458 analogue 
probes (L646, GY4, JC8, L505) have similar IC50s, but label the active site of γ-
secretase with different efficiencies (Tian et al., 2010a;Gertsik et al., 2015). 
Additionally, FAD mutations in PS1 hinder the labeling efficiency of some probes 
while having no perceptible impact on others (Chau et al., 2012). These findings 
suggest that all four active site-directed probes actually label different sub-sites of the 
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γ-secretase active site. Similarly to the L458 based probes, I propose to design 
additional CBAP-based probes by moving the benzophenone (or another 
photocrosslinking group) to other sites on the compound. This technique is known as 
“photophore walking.”  It is likely that synthesis of additional CBAP-based probes 
using the photophore walking approach will allow us to characterize the various sub-
sites of the γ-secretase active site, and more importantly, the PSase active site. The 
synthesis of distinct, photoreactive, clickable, CBAP-based probes that differ only in 
the location of the crosslinkable moiety can generate compounds that are optimized to 
label PS1-FL. My first recommendation is to make CBAP analogues that incorporate a 
benzophenone in the P1’ and P1 positions and to use these probes to pull-down PS1-
FL (Figure 2.7B). 
Based on current clinical investigation of non-selective γ-secretase inhibition (i.e. the 
case of semagacestat), PSase may not be a viable drug target for the treatment of AD 
since PSase inhibition also blocks γ-secretase activity, leading to toxicity (Doody et al., 
2013). However, PSase could serve as a target for cancer therapy. Furthermore, 
CBAP-BPyne can be used to investigate PSase and γ-secretase activation, which 
appear to play a role in disease states, as evidenced by reports that some FAD PS1 
mutations affect PSase activity (Mercken et al., 1996;Murayama et al., 1999;Brunkan 
et al., 2005b). CBAP-BPyne provides a novel means to investigate the mechanism of 
PSase as it has the capacity not only to bind and inhibit γ-secretase, but also to inhibit 
the endoproteolysis of PS1-FL, a novel function not observed in other γ-secretase 
probes. CBAP-BPyne may aid in the identification and characterization of PSase, 
revealing the mechanism of γ-secretase activation and uncovering PSase as a potential 
target in cancer therapy. 
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Figure 2.7. A. CBAP-BPyne, a dual γ-secretase and PSase clickable probe, inhibits 
both activities and provides a novel means to investigate the mechanism of 
endoproteolysis. B. Generation of alternative CBAP-based probes using the 
photophore walking approach. Each probe, with its benzophenone moiety on a 
different P position, crosslinks to a different sub-site of the enzyme active site. Left: 
clickable benzophenone is in the P1’ position. Right: clickable benzophenone is in the 
P1 position. 
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2.4 Methods 
Treatment of cells with compound followed by lysis and Western blot 
Cells were treated with compound at indicated concentration for 4-7 days, maintaining 
a final DMSO concentration of 0.1% (v/v). Cells were lysed with RIPA buffer (50 
mM Tris base pH 8.0, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% deoxycholate), and 
equal amounts of cell lysate was separated on a 12% Bis-Tris or a 4-20% TGX gel. 
Proteins were transferred to Immobilon-FL PVDF membrane, probed with indicated 
antibody, and imaged on Odyssey. 
Photoaffinity labeling followed by biotin pull-down and Western blot 
600 μg of HeLa cell membrane, diluted with PBS to a volume of 500 μL in a 12-well 
plate, was incubated with either 2 μM CBAP or vehicle control for 20 min at 37° C. 20 
nM CBAP-BPyne was added for 1 hour at 37° C followed by UV irradiation at 350 
nm for 45 min to promote benzophenone-protein crosslinking. Membrane was pelleted 
by centrifugation at 100,000 ×g for 30 min and resuspended in PBS using Qiagen 
TissueLyser. Click chemistry reagents [1 mM tris(2-carboxyethyl)phosphine, 1 
mM CuSO4, 0.1 mM tris-(benzyltriazolylmethyl)amine, and 0.1 mM biotin azide in 
5% t-butyl alcohol with 1% DMSO] were added and the mixture was rotated for 1 
hour at room temperature. Membranes were pelleted by centrifugation at 100,000 ×g 
for 30 min, resuspended in 500 μL PBS, and solubilized with the addition of RIPA 
buffer. Samples were centrifuged at 15,700 ×g and supernatant was added to Pierce 
Streptavidin Plus UltraLink Resin and rotated overnight at 4° C. Proteins were eluted 
with 2 mM biotin in SDS sample buffer at 70° C for 10 min, separated on a 12% Bis-
Tris gel or a 4-20% TGX gel, transferred to Immobilon-FL PVDF, probed with the 
relevant antibody, and visualized on Odyssey. 
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Photoaffinity labeling followed by CuAAC with TAMRA-azide 
See introduction for detailed method 
Live-cell photolabeling 
SH-SY5Y cells were plated to 60% confluence in 100x20 mm tissue culture dish. 
Next day cells were treated with 1 μM CBAP-BPyne (0.1% DMSO in media, v/v). 
After 24 hours, cells were split and half the cells were seeded in fresh media + 1 μM 
CBAP-BPyne. 24 hours later the media was removed and fresh media with 1 μM 
CBAP-BPyne was added. Samples were UV irradiated at 350 nm for 45 minutes on an 
ice block. Plate with samples was washed 2X with 5 ml cold PBS. Cells were scraped 
into Eppendorf tube in 1 ml PBS and spun down at 100 xg for 5 minutes. Supernatant 
was discarded. Cells were lysed in 1 mL cold PBS + PI by sonication, 6 x 0.5 second 
pulses. Low speed spin removed nuclear debris and supernatants were ultracentrifuged 
at 53,000 xg for 30 minutes. Supernatant from this spin was discarded and pellet was 
resuspended in 0.25% CHAPSO in PBS with TissueLyser. CuACC was performed as 
in 6.4. Samples were ultracentrifuged at 100,000 xg for 1 hour and pellets were 
resuspended with 1X RIPA in TissueLyser. Samples were spun down at 15,700 xg for 
10 min to pellet insoluble matter. The supernatants were transferred to a dolphin-nosed 
tube with 20 μl Streptavidin Plus UltraLink Resin and biotinylated proteins were 
pulled-down with rotation at 4˚ C overnight. The next day, samples were spun down at 
100 xg and supernatant was removed. The streptavidin slurry pellet was washed 3X 
with RIPA and once with tris buffered saline, 0.1% tween-20. Proteins were eluted 
with 40 μl of 2 mM biotin in Laemmli sample buffer at 70˚ C for 10 minutes and 20 μl 
of eluate was loaded and separated on SDS-PAGE. Proteins were transferred to PVDF 
membrane and probed with necessary antibodies. Similar protocol, without the 4-7 day 
pretreatment with CBAP-BPyne, was performed for ANP24 and ANPP8 cell labeling. 
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‡ Characterization of CBAP-BPyne: 1H NMR (400 MHz, CD3OD) δ 8.61 - 8.43 (m, 
1H), 8.26 (d, J = 8.8 Hz, 1H), 8.18 (t, J = 7.9 Hz, 1H), 7.82 - 7.75 (m, 2H), 7.73 - 7.67 
(m, 5H), 7.55 - 7.48 (m, 1H), 7.29 (t, J = 7.7 Hz, 1H), 7.24 - 7.08 (m, 13H), 7.08 - 
7.00 (m, 1H), 5.15 - 5.08 (m, 1H), 4.85 (2H, buried in solvent), 4.49 (dt, J = 13.5, 6.9 
Hz, 1H), 4.34 - 4.22 (m, 1H), 3.76 (td, J = 8.5, 4.3 Hz, 1H), 3.12 - 3.03 (m, 1H), 3.01 
(t, J = 2.3 Hz, 1H), 3.00 - 2.93 (m, 1H), 2.88 (d, J = 9.2 Hz, 1H), 2.82 - 2.69 (m, 2H), 
2.04 - 1.74 (m, 4H), 1.69 - 1.54 (m, 2H), 1.49 - 1.21 (m, 8H), 1.15 (d, J = 10.4 Hz, 
1H), 1.08 - 0.94 (m, 1H); LRMS calcd for C54H55N5O7 (M+H) 886.4, found 886.5; 
HPLC Purity: 99.9%. 
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CHAPTER 3 
γ-Secretase inhibitors (GSIs) and modulators (GSMs) induce distinct 
conformational changes in the active sites of γ-secretase and signal peptide 
peptidase (SPP) (Gertsik et al., 2015) 
3.1 Introduction 
γ-Secretase and signal peptide peptidase (SPP) are aspartyl proteases that catalyze 
regulated intramembrane proteolysis, a process that controls the activity and function 
of membrane proteins in all living systems studied to date (Brown et al., 2000). You 
can read Chapter 1 for a detailed introduction to γ-secretase. In this chapter we 
introduce SPP and the overlap between the two enzymes.  
The differences and similarities between γ-secretase and SPP 
SPP proteolyses signal peptides in their transmembrane (TM) region after they have 
been cleaved off from the protein by signal peptidase. The signal peptide fragments 
released by SPP are required for important cellular events such as immune 
surveillance by HLA-E epitopes and HCV polyprotein cleavage critical for viral 
lifecycle (Lemberg et al., 2001;McLauchlan et al., 2002). γ-Secretase and SPP are 
multi-span TM proteins that share the same YD/GXGD catalytic motif (Fluhrer et al., 
2009), but are structurally and functionally distinct (Figure 3.1). The key differences 
between the two proteins are: first, γ-secretase is a multi-subunit protein complex that 
includes Aph1, Nct, Pen2, and presenilin (PS, the catalytic subunit) (De Strooper, 
2003;Edbauer et al., 2003;Takasugi et al., 2003;Gertsik et al., 2014b). Unlike γ-
secretase, SPP appears to function alone without the participation of other protein co-
factors (Weihofen et al., 2002). Second, SPP and PS have opposite orientations within 
the membrane (Weihofen et al., 2002;Friedmann et al., 2004;Nyborg et al., 2004a). As 
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a consequence, γ-secretase cleaves type 1 TM substrates while the substrates of SPP 
are type 2. Third, endogenous, wild type PS is expressed as a full-length protein that is 
activated by endoproteolytic cleavage during protein maturation (Thinakaran et al., 
1996;Takasugi et al., 2003). Endoproteolysis results in the formation of two fragments, 
PS-NTF and PS-CTF, which remain associated within active γ-secretase complexes. 
Conversely, SPP functions as a full-length protein (Weihofen et al., 2002;Nyborg et al., 
2004b;Nyborg et al., 2006). There is evidence to suggest that SPP forms dimers and 
tetramers within the cell (Nyborg et al., 2004b;Nyborg et al., 2006;Miyashita et al., 
2011). 
 Figure 3.1. Structural and functional similarities/differences between γ-secretase 
and SPP. γ-Secretase and SPP are similar in that they are both multipass 
transmembrane enzymes that share the YD/GXGD catalytic motif and cleave their 
respective substrates in the transmembrane region. SPP and PS, the catalytic subunit 
of γ-secretase, both transverse the membrane nine times. The differences between the 
enzymes include their limited sequence homology, their inverse orientation in the 
membrane, and their specificity for either type 1 or type 2 substrates. Additionally, 
SPP functions without protein cofactors while PS requires at least 3 additional proteins 
(Aph1, Nct, and Pen2) for γ-secretase activity. 
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Although PS and SPP have opposite topologies with limited sequence homology, they 
share pharmacological characteristics: transition-state γ-secretase inhibitor L458 
inhibits SPP activity (Weihofen et al., 2003;Iben et al., 2007) and L458-based 
photoaffinity probes L852,646 (L646) and CBAP-BPyne specifically label SPP 
(Weihofen et al., 2003;Crump et al., 2012a;Gertsik et al., 2014a).  These data suggest 
structural similarity within the active sites of SPP and γ-secretase. 
Our approach to studying the highly similar active sites of these distinct enzymes 
Because there is no crystal structure of either γ-secretase or SPP, scant information 
exists regarding the active site architecture of these enzymes. Moreover, a comparison 
study exploring the effect of γ-secretase inhibitors (GSIs) and modulators (GSMs), 
which are being developed for cancer and AD treatment, on the active sites of SPP and 
γ-secretase has not been reported. We use a chemical biology approach to probe the 
active sites of PS1 and SPP. Particularly, we employ active site-directed photoprobes, 
in a method called photophore walking, to target the various sub-pockets of the 
enzyme active site (see Chapter 1 for detailed introduction to this technique) (Shelton 
et al., 2009;Tian et al., 2010a;Crump et al., 2011;Chau et al., 2012;Crump et al., 2013) 
(Figure 3.2A). Comparison of the photolabeling profiles of PS1 and SPP demonstrated 
that the active sites of these proteins are similar, yet some differences are apparent in 
specific active site sub-pockets. Furthermore, we used the photophore walking 
approach to determine the effects of GSIs and GSMs on the active site conformations 
of γ-secretase and SPP, which is an important step toward understanding off-target 
effects of GSI and GSM treatment. In addition, we provide evidence that active SPP 
exists as a stable homodimer. 
 
58  
3.2 Results  
PS1 and SPP active site conformations are similar yet distinct 
L458 has been a valuable tool in the study of γ-secretase (Shearman et al., 2000). We 
incorporated a photoreactive benzophenone moiety into different side chain positions 
of L458 (P and P’ sites) to generate a series of photoprobes. These photoprobes, JC8, 
L646, GY4, and L505, photocrosslink to S1’, S2, S1, or S3’ subsites within the γ-
secretase active site, respectively (Li et al., 2000b;Shelton et al., 2009;Yang et al., 
2009;Tian et al., 2010a) (Figure 3.2A). A biotin linker was attached for isolation of the 
labeled species. This photophore walking approach facilitates the comparison of active 
site conformational changes of target enzymes, as the photocrosslinking efficiency is 
determined by the distance and orientation between contact residues of the enzyme 
active site and the benzophenone moiety of the photoprobes. By comparing the 
photocrosslinking efficiency of each probe to PS1 and SPP, we can gain insight into 
the conformational differences between the active sites of these enzymes. 
Total membrane isolated from HeLa cells was used as the source of endogenous γ-
secretase and SPP. First, we confirmed that JC8, L646, GY4, and L505 photolabeled 
PS1-NTF and this labeling was specific since excess amount of L458 blocked the 
labeling (Figure 3.2B, middle panel). Furthermore, the photolabeling profile of PS1-
NTF revealed that JC8 labeled PS1-NTF with the strongest intensity followed by L646. 
GY4 and L505, on the other hand, were both weaker photoprobes for PS1-NTF 
(Figure 3.2B, middle panel). 
SPP was photocrosslinked with the same set of photoprobes and the labeling was 
specific as excess L458 was able to block the photoinsertion of the probes (Figure 
3.2B, top panel). Additionally we used (Z-LL)2-ketone, a peptidomimetic SPP 
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inhibitor with an in vitro IC50 of 50 nM (Weihofen et al., 2000), to confirm that SPP is 
being specifically labeled and inhibited in our system (Figure 3.2C). As expected, 
excess (Z-LL)2-ketone blocked the photolabeling of SPP completely (Figure 3.2C, top 
panel) but had little effect on the photolabeling of PS1-NTF (Figure 3.2C, bottom 
panel). Additionally, we showed that the photolabeling profile of SPPL2A, a close 
homologue of SPP that cleaves different substrates, is different from that of both γ-
secretase and SPP. L646 and L505 labeled SPPL2A most efficiently, with the other 
photoprobes showing weaker labeling (Figure 3.2B, bottom panel).  
These results indicate that the photolabeling profiles of PS1, SPP, and SPPL2A are 
different. Here we focus on the differences between PS1and SPP: Although JC8 
labeled both PS1 and SPP with the strongest intensity, L646 was a much weaker 
photoprobe for SPP. Instead, L505 photolabeled SPP with similar efficiency to JC8. 
GY4 was a weaker photoprobe for both PS1 and SPP (Figure 3.2B). Comparison of 
the PS1 and SPP photolabeling profiles reveals that while two probes label the 
enzymes with similar efficiency (JC8 and GY4), the other two probes exhibit opposite 
labeling efficiencies (L646 and L505), suggesting that γ-secretase and SPP have 
similar architecture of the S1’ and S1 sub-pockets, whereas the S2 and S3’ sub-
pockets are organized differently (Figure 3.2D). In conclusion, the overall structures 
of the PS1, SPP, and SPPL2A active sites are similar since the enzymes can be 
specifically labeled by all four active site-directed photoprobes, but the structure of the 
active site subsites differs among the enzymes, exemplified by the difference in 
labeling efficiency among photoprobes. How variation of these subsites contributes to 
the activity and specificity of γ-secretase, SPP, and SPPL2A remains to be 
investigated. 
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Figure 3.2. L458-based photoreactive probes specifically label PS1 and SPP. A. 
Structures of L458 and photoreactive probes JC8, L646, GY4, and L505. L458 side 
chain residues (P and P’ sites) interact with corresponding sub-pockets of γ-secretase 
and SPP (S and S’ sites). Photoreactive probes JC8, L646, GY4, and L505 have an 
L458 backbone (black), a biotin moiety (green), and a crosslinkable benzophenone 
(BP). Each probe has a BP incorporated into a different site on the L458 backbone. 
The location of the BP is illustrated by the color scheme. For example, JC8 has a BP at 
the P1’ site, in place of the red benzene ring. JC8, L646, GY4, and L505 label S1’, S2, 
S1, and S3’ subsites of the enzymes, respectively. B. HeLa membranes were labeled 
with 20 nM of photoprobes JC8, L646, GY4, or L505 in the presence of 0.25% 
CHAPSO, and either with (+) or without (-) 2 μM L458. Samples were run on SDS-
PAGE and analyzed by Western blot. Anti-SPP, PS1-NTF, or SPPL2A antibodies 
were used to detect SPP (top panel), PS1-NTF (middle panel), or SPPL2A (bottom 
panel). C. Same as B, except 2 μM (Z-LL)2-ketone was used to block the labeling of 
SPP (top panel) and PS1-NTF (bottom panel). D. Active site-directed probes show 
subtle differences in the structures of PS1, SPP, and SPPL2A active sites. Ovals – the 
active site. Stars – the active site-directed probes. Smaller ovals, in which there is a 
closer interaction between enzyme active site and probe, represent tighter binding 
/higher efficiency of probe binding. Bigger ovals represent lower efficiency of probe 
binding.
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Figure 3.2 
 
62  
Active SPP exists predominantly as a homodimer  
Initial characterization of SPP showed that endogenous SPP is a monomer (Weihofen 
et al., 2002;Weihofen et al., 2003). Further studies by Nyborg et al. demonstrated that 
SPP is a homodimer that is SDS-stable and partially heat-labile (Nyborg et al., 
2004b;Nyborg et al., 2006). However, only the monomeric form of SPP was labeled 
with the active site-directed photoprobe III-63 (Sato et al., 2006;Sato et al., 2008). 
Additionally, endogenous n-Dodecyl β-D-maltoside (DDM)-solubilized human and 
drosophila SPP formed higher molecular weight complexes around 180-200kDa 
(Miyashita et al., 2011). We utilized a photolabeling approach to elucidate whether 
endogenous active SPP is a homodimer or monomer. We synthesized JC10, a 
photoprobe structurally similar to JC8 except with the addition of a disulfide bond in 
the biotin linker that can be eluted from the streptavidin matrix with the reducing agent 
TCEP (Figure 3.3A) (Chun et al., 2004). Our data showed that the majority of SPP 
was monomeric when heat was used to elute SPP from JC8 (Figure 3.3B, first panel), 
with some residual SPP dimer still detected. However, in the absence of heat, JC10 
photolabeled SPP was predominantly a homodimer (Figure 3.3B, third panel). Similar 
to the SPP labeled with JC8 (Figure 3.2B, C and 3.3B), most of the SPP dimer was 
converted into the monomer when heat was applied (Figure 3.3B, fourth panel). This 
confirmed the finding that dimer SPP is heat-labile and provided further evidence that 
endogenous, active SPP exists as a homodimer. To detect predominantly SPP dimer 
we eluted proteins with Laemmli Sample Buffer + 2 mM biotin at 70° C. Under these 
conditions SPP does not dissociate into its monomeric form (Figure 3.3B, second 
panel). As a result, we show only SPP dimer in subsequent experiments. 
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Figure 3.3. Endogenous, active SPP is a homodimer. A. Structures of JC8, JC10, 
and schematic of experimental protocol. HeLa membrane was labeled either with JC8 
or JC10, UV crosslinked and pulled-down with streptavidin beads. JC8-labeled sample 
can be eluted with heat and JC10 labeled sample can be eluted with TCEP. B. JC8 and 
JC10 were used to photolabel SPP. TCEP and/or different degrees of heat were used to 
elute photolabeled proteins
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Figure 3.3 
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GSIs and GSMs have opposite effects on the active site conformational changes of PS1 
and SPP 
We have previously used photoprobes to detect γ-secretase active site conformational 
changes induced by the binding of GSIs and GSMs (Shelton et al., 2009;Tian et al., 
2010a;Crump et al., 2011). However, the effect of GSIs and GSMs on the active site 
conformation of SPP has not been reported.  
We investigated the effects of four GSIs and two GSMs on the active site 
conformations of γ-secretase and SPP (Figure 3.4). GSIs inhibit production of Notch 
intracellular domain (NICD) and all Aβ species including Aβ40 and Aβ42 while 
GSMs have little impact on NICD production and selectively inhibit production of 
Aβ42 (Crump et al., 2013). BMS-708163, commonly known as avagacestat, was 
discordantly reported as both a Notch-sparing GSI (Gillman et al., 2010) and a 
nonselective GSI (Chavez-Gutierrez et al., 2012;Crump et al., 2012b), that completed 
phase II clinical trials but did not proceed any further. LY450139, also known as 
semagacestat, advanced into a Phase III clinical trial but was terminated prematurely 
due to side effects potentially stemming from Notch-associated toxicity (Doody et al., 
2013). Compound X (cpd X) and GSI-34 are both GSIs (Placanica et al., 2010;Yang et 
al., 2010). E2012 is an imidazole-derived GSM which has been shown to bind SPP 
(Pozdnyakov et al., 2013), and GSM-616 is an acetic acid GSM  that binds SPP 
(Crump et al., 2011). 
We tested the effects of BMS-708163, LY450139, cpd X, and GSI-34 on the 
photolabeling of PS1 and SPP by active site-directed probes. The effect of these GSIs 
was assessed by comparison to vehicle control. As anticipated, these GSIs inhibited 
the photolabeling of PS1-NTF (Figure 3.4D). Surprisingly, they selectively enhanced 
the labeling of SPP (Figure 3.4C). These data suggest that the GSIs tested have 
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opposite effects on the active site conformations of SPP and γ-secretase. The increase 
in SPP labeling in the presence of GSIs may be due to a direct interaction between the 
GSI and SPP, leading to a change in SPP active site conformation that improves 
labeling with the active site-directed probe. Alternatively, the increase in labeling may 
be due to increased availability of the active site-directed probe as a result of a 
reduction in the number of active γ-secretase complexes available for binding. The 
latter hypothesis does not require direct binding between GSIs and SPP, and is based 
on the data that shows a reduction in PS1 labeling in the presence of GSIs (Figure 
3.4B and D), which may suggest that the active site-directed probes that are not 
engaged in labeling PS1 are labeling SPP. While both hypotheses are feasible 
explanations for the increase in SPP labeling in the presence of GSIs, the data support 
the “direct labeling” hypothesis for the following reasons: First, in the presence of 
GSIs, SPP labeling is enhanced for some, but not all, active site-directed probes. If the 
increase in SPP labeling were a result of an increase in probe availability, all active 
site-directed probes would be expected to label SPP more robustly, but we do not 
observe this. Second, Fuwa et al. found that a compound E-based probe, which is 
identical to cpd X with the exception of a single hydroxyl group, specifically labels 
SPP, showing direct binding between this GSI and SPP (Fuwa et al., 2007). For these 
reasons it is likely that the GSIs studied here are directly binding SPP. We also tested 
the effects of E2012 and GSM-616 on the photolabeling of PS1 and SPP. Although 
these GSMs have been shown to modulate γ-secretase activity (Crump et al., 
2011;Pozdnyakov et al., 2013), they had little effect on the active site labeling of PS1-
NTF (with the exception of the S1 subsite for GSM-616), suggesting that these 
compounds affect γ-secretase activity without drastically altering the active site 
conformation (Figure 3.4D). More interestingly, these GSMs partially reduced the 
active site labeling of SPP by all photoprobes except L646 (Figure 3.4C), suggesting 
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that both of these structurally distinct GSMs affect the same sub-pockets of the SPP 
active site. Additionally, we and others have reported that GSM-1, which is a close 
homologue of GSM-616, and GSM E2012, directly bind SPP (Crump et al., 
2011;Pozdnyakov et al., 2013). 
The combined data show that while GSIs inhibit labeling of PS1 and have no effect on 
or enhance labeling of SPP, the opposite is true of GSMs, which inhibit labeling of 
SPP and have little to no effect on labeling of PS1. A clear exception is the 
pronounced increase in GY4 labeling of PS1 in the presence of GSM-616 (Figure 
3.4D), which was previously reported (Crump et al., 2011). The trend, therefore, is 
that GSIs and GSMs have opposite effects on the photolabeling profiles of γ-secretase 
and SPP (Figure 3.5). The data suggest that not only GSMs, as previously reported, 
but also GSIs directly bind to SPP, potentially leading to the observed conformational 
change in its active site. Consequently, GSIs in clinical trials for cancer and GSMs 
developed for AD treatment may lead to undesirable effects associated with 
concomitant changes in SPP structure. This possibility is worth studying as SPP is 
essential in eukaryotes (Grigorenko et al., 2004;Casso et al., 2005;Krawitz et al., 
2005) and a change in its activity and specificity may affect the therapeutic windows 
of GSIs and GSMs.  
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Figure 3.4. GSIs and GSMs have opposite effects on the photolabeling profiles of 
γ-secretase and SPP. A. Structures of E2012, GSM-616, BMS-708163, LY450139, 
cpd X and GSI-34. B. Photoprobes JC8, L646, GY4 and L505 were incubated with 
HeLa membrane in 0.25% CHAPSO in the presence of 25 uM GSMs E2012/616, 
(green) or 10 uM GSIs 708163/139/cpd X/GSI-34 (blue). Samples were run on SDS-
PAGE and analyzed by western blot. Anti-SPP and PS1-NTF antibodies were used to 
detect SPP (top panel) and PS1-NTF (bottom panel). C. Densitometry quantification 
of SPP labeling. GSMs are graphed in green, GSIs are graphed in blue. D. Same as C, 
except PS1-NTF. ns P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001 
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Figure 3.4 continued 
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3.3 Conclusion and Discussion 
Determining allosteric site-induced conformational changes in the active sites of 
enzymes for which atomic resolution is not available has been a big challenge. To 
address this, we developed and applied the photophore walking technique for probing 
the active sites of two such enzymes, γ-secretase and SPP. We found that while the S1’ 
and S1 sub-pockets of both enzymes are similar, the S2 and S3’ sub-pockets are 
structurally distinct. The strong overall similarity in the active sites of these two 
enzymes that cleave entirely different substrates may mean that the active site does not 
play an important role in determining substrate specificity. On the flipside, some 
substrate specificity may be conferred by the subtle differences in two of the four 
active site sub-pockets. It is possible that the conserved structure of the S1’ and S1 
subsites is a result of the importance of these subsites in catalysis. We were surprised 
to find that the active sites of γ-secretase and SPP are differently affected by allosteric 
GSIs and GSMs. Despite the strong structural homology of the active sites of these 
enzymes, GSIs had a diametrical impact on the conformations of the two enzyme 
active sites, as gauged by interaction with active site-directed probes (Figure 3.5). 
Although enzyme binding to active site-directed probes is not a direct proxy for 
activity, there is a high likelihood that if the active site is changing, so is enzyme 
activity/specificity. This has important ramifications for drug development, as changes 
in SPP activity may occur during GSI/GSM treatment.  
Semagacestat and avagacestat were both terminated in late phase clinical trials due to 
toxicity. The precise cause of the toxicity remains unknown, but we and others believe 
it is probably “mechanism-based,” meaning that the drugs’ interaction with its γ-
secretase target is what caused the Notch-associated non-melanoma skin cancer and 
GI toxicity. However, this does not rule out the possibility that off-target toxicities 
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compounded this problem. For most drug candidates, the identities of the off-target 
interacting proteins is not known, but GSIs and GSMs are the rare case in which SPP 
has been identified as a potential off-target binding partner. In 2002, a homology 
search on SPP revealed PS as an ortholog (Weihofen et al., 2002), and today we know 
that this very structural conservation may pose a threat to GSI/GSM development. 
Through the above experiments we have taken the first step to understanding how SPP 
is structurally impacted by GSIs and GSMs. If we are to bring these drugs to the clinic 
we must harness and augment the vast work that has been done in understanding their 
mechanism of action not only with respect to γ-secretase, but also with respect to other, 
albeit unintended, targets.  
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Figure 3.5. Model for the change in active site conformation of γ-secretase and 
SPP that occurs upon binding by GSIs and GSMs. We propose that the GSIs and 
GSMs studied here allosterically bind to γ-secretase and SPP, causing a 
conformational change in the active sites of the enzymes. Surprisingly, the induced 
conformational change is opposite for the two enzymes, as evidenced by their binding 
to active site-directed probes. Specifically, GSIs cause decreased binding between γ-
secretase and probe while increasing binding between SPP and probe. GSMs cause 
little change in binding between γ-secretase and probe but reduce binding between 
SPP and probe. This suggests a model in which GSIs cause the active site of γ-
secretase to assume a “closed” conformation, but have the reverse impact on the active 
site structure of SPP.  
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3.4 Methods 
HeLa cell membrane preparation and chemicals 
HeLa membrane fraction was isolated from HeLa-S3 cells (National Cell Culture 
Center) as previously described (Li et al., 2000b;Tian et al., 2010a). Synthesis of L458, 
cpd X, GSI-34, L646, GY4, JC8, L505, and (Z-LL)2-ketone were described previously 
(Li et al., 2000b;Seiffert et al., 2000;Shearman et al., 2000;Weihofen et al., 2000;Chun 
et al., 2004;Yang et al., 2009). LY450139, BMS-708163, E2012, and GSM-616 were 
kindly provided by Dr. Douglas Johnson from Pfizer.       
Peptide synthesis and anti-SPP antibody production   
SPP peptide corresponding to the N-terminal of human SPP 
(MDSALSDPHNGSAEAC) was synthesized by Dr. Deming Chau with an automated 
solid phase peptide synthesizer (ProteinTech) using Fmoc chemistry. The purified 
peptide was conjugated to maleimide functionalized keyhole limpet hemocyanin 
(KLH) according to the manufacturer’s instructions (Pierce). This antigen was used to 
immunize rabbits for polyclonal antibody produc tion (Covance). Serum was collected 
and tested for SPP detection using Western blot analysis.   
Photolabeling of γ-secretase and SPP  
Total HeLa cell membrane was pre-incubated in the presence of 0.25% CHAPSO with 
or without inhibitors at 37° C for 30 minutes (Li et al., 2000b;Crump et al., 2011;Chau 
et al., 2012;Crump et al., 2012b;Gertsik et al., 2014a). Then, 20 nM of photoactive 
probes was added to the mixture and incubated for an additional 1 hour at 37°C. The 
reaction mixtures were irradiated at 350 nm for 45 minutes and solubilized with RIPA 
buffer (50 mM Tris base, pH 8.0, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% 
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deoxycholate) for 1 hour. Photocrosslinked proteins in the soluble fraction were 
pulled-down with Streptavidin Plus UltraLink Resin (Pierce) overnight at 4° C. The 
resin was washed with RIPA buffer and proteins were eluted with Laemmli Sample 
Buffer (32.9 mM Tris-HCl, pH 6.8, 1% SDS, 13% (w/v) glycerol, 0.005% 
bromophenol blue) at 95° C (Figure 3.2 and 3.3), 25 mM TCEP in PBS (Figure 3.3), 
or 2 mM biotin in Laemmli Sample Buffer at 70° C (Figure 3.4). Eluted proteins were 
resolved on SDS-PAGE and transferred to PVDF (Millipore). PS1-NTF, PS1-CTF, 
SPP, and SPPL2A were detected with anti-PS1-NTF (gift from Dr. Min Xu), anti-
PS1-CTF (Millipore), anti-SPP, or anti-SPPL2A epitope 8 (gift from Dr. Bernd 
Schroder) antibody.  
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CHAPTER 4 
Mapping the binding site of BMS-708163, a γ-secretase inhibitor, using cleavable 
linker probes 
4.1 Introduction 
γ-Secretase’s complexity, flexibility, and hydrophobicity have caused it to be 
refractory to crystallization, making high resolution drug-target studies particularly 
challenging. A recent 3.4 Å cryo EM structure (Bai et al., 2015b) of γ-secretase has 
begun to shed some light on the way in which the enzyme’s structure may account for 
its highly regulated yet fairly promiscuous function (Gertsik et al., 2014b), but many 
questions about γ-secretase’s active site and interaction with clinically relevant small 
molecules remain.  
Avidin-based pull-down of biotin labeled proteins has been used widely to study 
interactions between proteins and small molecules. In particular, this tool, coupled 
with photoaffinity labeling, allowed for the identification of presenilin (PS) as the 
active subunit of γ-secretase (Li et al., 2000b), and for the identification of γ-secretase 
as the target of γ-secretase modulators (GSMs) (Crump et al., 2011). However, the 
affinity of the biotin-(strept)avidin interaction (Kd ~ 10-15 M) (Green, 1990) means that 
harsh conditions, such as boiling (Li et al., 2000b), excess biotin (Gertsik et al., 2015), 
or on-bead trypsin digestion (Dieterich et al., 2007), are required for elution. The 
concomitant elution of non-specific proteins that occurs during such stringent 
procedures can be tolerated for some studies, for example when the identity of the 
protein of interest is known, but is suboptimal for others, especially if they include 
mass spectrometry. Cleavable linkers that require mild cleavage conditions may be the 
solution to avoiding protein contamination in the eluted sample. In addition to 
reducing contamination, mild elution of cleavable linkers accomplishes another 
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significant feat: it separates the reactive end of the molecule from the bulky, 
hydrophobic biotin group. This is particularly important for studying transmembrane 
proteins, like γ-secretase, which may become too hydrophobic for mass spectrometry 
detection when attached to biotin. 
γ-Secretase inhibitors (GSIs), which are in clinical trials for cancer, pan-inhibit γ-
secretase and prevent it from cleaving its substrates, including APP and Notch. GSMs, 
which are promising AD therapies, reduce levels of the amyloidogenic Aβ42 while 
maintaining total Aβ levels constant and without impeding Notch signaling. The 
interaction between γ-secretase and GSIs/GSMs has been explored in a variety of 
ways, including photoaffinity labeling (Li et al., 2000b;Seiffert et al., 2000;Kornilova 
et al., 2005;Fuwa et al., 2007;Shelton et al., 2009;Tian et al., 2010a;Crump et al., 
2011;Crump et al., 2012a;Crump et al., 2012b;Gertsik et al., 2014a;Gertsik et al., 
2015), fluorescence lifetime imaging (FLIM) (Lleo et al., 2004;Uemura et al., 2010), 
and surface cysteine accessibility method (SCAM) (Ohki et al., 2011). These studies 
provided insight into the mechanisms of GSIs/GSMs, but to our knowledge there have 
been no reports that mapped the precise GSI/GSM binding site on γ-secretase. Here 
we develop BMS-708163-based photoactive (Crump et al., 2012b), cleavable probes 
for the study of γ-secretase, provide a side-by-side comparison of their efficiency for 
photolabeling and eluting PS1-NTF, and identify a binding site of the GSI BMS-
708163 (avagacestat) on PS1. 
4.2 Results 
BMS-708163-based probes are potent inhibitors of γ-secretase and target PS1-NTF 
We designed four biotinylated BMS-708163-based probes with various cleavable 
linkers in order to expand the arsenal of tools with which to study γ-secretase (Figure 
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4.1A). BP-DDE can be cleaved with hydrazine (H2N2) (Yang and Verhelst, 2013), BP-
vicinal diol can be cleaved by oxidation with sodium periodate (NaIO4)  (Yang et al., 
2013), BP-azobenzene can be cleaved by reduction with sodium hydrosulfite 
(Na2S2O4) (Blum et al., 2013), and BP-DADPS can be cleaved by formic acid (CH2O2) 
(Szychowski et al., 2010;Wang et al., 2015). We also included BP-biotin which does 
not have a cleavable linker and can be eluted with heat. We established that all five 
probes are potent γ-secretase inhibitors as they have IC50s in the low nanomolar range, 
just like parent compound BMS-708163 (Figure 4.1B). However, the IC50s of the 
probes varied slightly, with BP-vicinal diol being the most potent inhibitor of Aβ40 
production (IC50 = 1.1 nM) and BP-DADPS being the least potent (IC50 = 8.0 nM). 
Clearly, the presence of different linkers affects IC50 in spite of the fact that the linker 
is significantly removed from the reactive end of the molecule.  
Next we performed a side-by-side comparison of the efficiency of PS1-NTF 
photolabeling by all probes (Figure 4.1C). HeLa membrane was photolabeled with 20 
nM of each probe in the presence of 0.25% CHAPSO, samples were pulled-down with 
streptavidin beads, eluted with 2 mM biotin in Laemmli sample buffer at 70˚ C for 10 
minutes, resolved on SDS-PAGE, and probed for PS1-NTF. PS1-NTF was robustly 
and specifically labeled by all probes, with some variation in labeling efficiency 
evident among different probes. Comparing among the cleavable linker probes, BP-
vicinal diol and BP-DDE label PS1-NTF most robustly while BP-azobenzene and BP-
DADPS show weaker labeling. The photolabeling profile of the probes closely reflects 
the IC50s: the two most potent probes (BP-DDE and BP-vicinal diol) label PS1-NTF 
with higher efficiency while the two least potent probes (BP-azobenzene and BP-
DADPS) label PS1-NTF with lower efficiency. This finding is reassuring, as it 
suggests that the photolabeling efficiency of these probes is predominantly a function 
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of IC50 and less a function of the orientation of the benzophenone with respect to the 
protein. 
We attempted to obtain equal labeling among all probes by correcting for IC50 (Figure 
4.1D). The IC50 of each probe was multiplied by 50 (10X to saturate the γ-secretase 
binding sites and 5X to make up for the fact that we have a 5X higher concentration of 
HeLa membrane in the photolabeling reaction than we do in the activity assay) and 
HeLa membrane was labeled with this corrected concentration. Samples were pulled-
down, eluted, and Western blotted as in Figure 4.1C. We were able to get closer to 
equal labeling by using these adjusted concentrations, although BP-azobenzene 
labeling was still lower than that of other probes. 
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Figure 4.1. A. Structures of parent compound BMS-708163 and probes BP-biotin, 
BP-DDE, BP-vicinal diol, BP-azobenzene, and BP-DADPS. B. In vitro inhibitory 
potency (IC50) of BMS-7081635 and five BMS-708163-based probes. C. HeLa 
membrane was photolabeled with 20 nM BP-DDE, BP-vicinal diol, BP-azobenzene, 
BP-DADPS, or BP-biotin in the presence (+) or absence (-) of 1 μM BMS-708163. 
Samples were pulled-down with streptavidin beads, eluted with 2 mM biotin in 
Laemmli sample buffer at 70˚ C, run on SDS-PAGE, and analyzed by Western blot. D. 
HeLa membrane was photolabeled with 95 nM BP-DDE, 55 nM BP-vicinal diol, 140 
nM BP-azobenzene, 400 nM BP-DADPS, or 165 nM BP-biotin. Samples were treated 
the same as in “1C.” Densitometry quantification of PS1-NTF labeling (right panels 
for C and D).
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Figure 4.1 
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Figure 4.1 continued 
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Comparison of PS1-NTF elution efficiency for all cleavable probes 
We used these IC50-adjusted concentrations to optimize elution conditions for all 
cleavable probes (Figure 4.2). While three of the four probes (BP-DDE, BP-vicinal 
diol, BP-azobenzene) photolabel and release PS1-NTF efficiently, BP-DADPS is not 
compatible with PS1-NTF due to instability of the protein in formic acid. Different 
concentrations of eluting reagent + SDS (0.05-1%) were tried for all probes. Only 
optimized conditions are shown (Figure 4.2). Briefly, we labeled 400 μg of HeLa 
membrane with IC50-adjusted concentration of photoprobe, pulled-down with 
streptavidin beads, and eluted samples twice with cleavage-specific conditions. We 
then washed samples thoroughly with 0.1% SDS to remove eluted proteins and 
cleavage reagents and eluted a third time with 2 mM biotin in Laemmli sample buffer 
at 70˚ C for 10 minutes. Equivalent amounts of each elution was loaded onto SDS-
PAGE and analyzed by Western blot, probing for PS1-NTF. Cleavage of BP-DDE 
with 2% hydrazine + 0.05% SDS resulted in exhaustive elution of PS1-NTF such that 
subsequent elution with 2 mM biotin in Laemmli sample buffer at 70˚ C for 10 
minutes (elution 3) was not able to recover any additional protein (Figure 4.2A). In 
contrast, cleavage-specific elution of BP-vicinal diol, BP-azobenzene, and BP-DADPS 
all showed some elution of PS1-NTF, but PS1-NTF was also present in subsequent 
heat elution samples (Figure 4.2B-D). This illustrates that elution by cleavage-specific 
conditions is not complete for any probe tested except BP-DDE.  
To directly compare cleavage/elution capacity of probes, we labeled HeLa membrane 
with IC50-adjusted concentrations of photoprobes BP-DDE, BP-vicinal diol, and BP-
azobenzene in triplicate and then eluted samples with either cleavage specific 
conditions or 2 mM biotin in Laemmli sample buffer at 70˚ C for 10 minutes (Figure 
4.2E, bottom panel). We analyzed samples by Western blot and normalized cleavage-
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specific bands to heat eluted bands. We then normalized that signal to BP-DDE, and 
graphed the results (Figure 4.2E, bottom panel). For a representative Western blot, see 
Figure 4.2E, top panel. BP-DDE is far superior to the other probes at capturing and 
eluting PS1-NTF: Specifically, the PS1-NTF signal of BP-DDE is ~4X higher than 
that of BP-vicinal diol and ~3X higher than that of BP-azobenzene.  
Elution of BP-DDE bound PS1-NTF with hydrazine and SDS is 100% efficient 
Interestingly, when HeLa membrane was photolabeled with BP-DDE, elution of PS1-
NTF with hydrazine was 2X higher than elution of PS1-NTF with 2 mM biotin in 
Laemmli sample buffer at 70˚ C for 10 minutes (data not shown). This was surprising 
as we expected heat elution to always be stronger than elution with cleavage-specific 
reagents. At first we hypothesized that the reason hydrazine elution appears higher 
than heat elution is because hydrazine causes proteins to run/transfer/bind antibody 
differently than does sample buffer. To test this, we added hydrazine to samples eluted 
with sample buffer + heat and compared those samples to hydrazine eluted samples. 
Addition of hydrazine to heat eluted samples did not improve the PS1-NTF signal on 
Western blot (data not shown), suggesting that the presence of hydrazine was not 
causing any artifact leading to signal enhancement.  
Alternatively, we hypothesized that the reason hydrazine elution is stronger than heat 
elution is because heat elution is not comprehensive and leaves some PS1-NTF either 
bound to the streptavidin beads or aggregated. We confirmed this hypothesis by 
eluting BP-DDE with various sample buffer + detergent + heat conditions and finding 
that the addition of Triton X-100 to sample buffer actually improves heat elution and 
brings its efficiency closer to that of hydrazine (Figure 4.2F). This reaffirms the 
finding that elution of BP-DDE labeled PS1-NTF with cleavage-specific conditions 
detailed here is ~100% efficient. Cleavage of BP-vicinal diol with sodium periodate is 
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2X less efficient at eluting PS1-NTF than is heat elution of the same probe, and 
cleavage of BP-azobenzene with sodium hydrosulfite is 4X less efficient at eluting 
PS1-NTF than is heat elution of the same probe. The combined data suggest either that 
BP-DDE, once bound to the enzyme, is more readily cleaved than the other probes or 
that PS1-NTF is more stable/soluble in hydrazine than in the other cleavage reagents.  
BP-DADPS is a poor probe for PS1-NTF as PS1-NTF is unstable at low pH 
Elution of BP-DADPS with 1 or 5% formic acid in the absence or presence of SDS 
did not show any PS1-NTF on the Western blot (Fig. 4.2D). We hypothesized that the 
low pH of the sample interfered with SDS-PAGE, so we neutralized all samples with 
Tris-OH (data not shown). However, even after samples had been brought back to 
neutral pH and run on SDS-PAGE, there was no PS1-NTF signal on the Western blot. 
Next, we hypothesized that PS1-NTF is unstable in extremely acidic conditions so we 
tried eluting proteins with 100 or 500 mM glycine HCl, pH=2 or 3 in the absence or 
presence of SDS (data not shown). However, these conditions were unable to cleave 
BP-DADPS and elute proteins. We noticed that adding sample buffer to sample in 5% 
formic acid yielded a nice PS1-NTF band, but transferring acidic sample from one 
tube to the other and then adding sample buffer yielded no band. This led us to believe 
that PS1-NTF may be aggregating and precipitating out of solution at low pH, but can 
be resolubilized with the addition of sample buffer. To test whether PS1-NTF can be 
stabilized at low pH, we eluted proteins with 1 or 5% formic acid with 0.1 mg/ml BSA 
(Figure 4.2D). The addition of BSA stabilized PS1-NTF so that it finally became 
visible on Western blot. Interestingly, PS1-NTF was only visible when SDS was 
absent. The reason for this is that SDS precipitates BSA under low pH. We tried 
adding BSA to other cleavage reagents, such as 2% hydrazine, in order to see whether 
BSA can stabilize PS1-NTF in the absence of SDS. However, we were unable to 
86  
detect PS1-NTF under these conditions. While BP-DADPS is not a viable probe for γ-
secretase due to the low pH conditions required for protein elution, it may well work 
for other, more hydrophilic candidates (Szychowski et al., 2010).  
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Figure 4.2. A. PS1-NTF labeled with BP-DDE and eluted with hydrazine (N2H4). 
HeLa membrane was photolabeled with 95 nM BP-DDE and pulled-down with 
streptavidin beads. Samples A, B, and C were eluted two times with 2% hydrazine + 
varying amounts of SDS (elutions 1 and 2). They were then eluted a third time with 2 
mM biotin in Laemmli sample buffer at 70˚ C for 10 minutes (elution 3). Sample D 
was eluted only with 2 mM biotin in Laemmli sample buffer at 70˚ C for 10 minutes. 
B. PS1-NTF labeled with BP-vicinal diol and eluted with sodium periodate (NaIO4). 
HeLa membrane was photolabeled with 55 nM BP-vicinal diol and pulled-down with 
streptavidin beads. Samples A, B, C, and D were eluted two consecutive times with 10 
or 20 mM sodium periodate +/- 0.5% SDS (elutions 1 and 2). They were then eluted a 
third time with 2 mM biotin in Laemmli sample buffer at 70˚ C for 10 minutes (elution 
3). Sample E was eluted only with 2 mM biotin in Laemmli sample buffer at 70˚ C for 
10 minutes. C. PS1-NTF labeled with BP-azobenzene and eluted with sodium 
hydrosulfite (Na2S2O4). HeLa membrane was photolabeled with 140 nM BP-
azobenzene and pulled-down with streptavidin beads. Samples A and B were eluted 
two consecutive times with 25 mM sodium hydrosulfite +/- 0.05% SDS (elutions 1 
and 2). They were then eluted a third time with 2 mM biotin in Laemmli sample buffer 
at 70˚ C for 10 minutes (elution 3). Sample C was eluted only with 2 mM biotin in 
Laemmli sample buffer at 70˚ C for 10 minutes. D. PS1-NTF labeled with BP-DADPS 
and eluted with formic acid (CH2O2). HeLa membrane was photolabeled with 400 nM 
BP-DADPS and pulled-down with streptavidin beads. Samples A, B, C, and D were 
eluted once with 1% or 5% formic acid +/- 0.5% SDS, all in the presence of 0.1 mg/ml 
BSA (elution 1). They were then eluted a second time with 2 mM biotin in Laemmli 
sample buffer at 70˚ C for 10 minutes (elution 2). Sample E was eluted only with 2 
mM biotin in Laemmli sample buffer at 70˚ C for 10 minutes. All samples were run on 
SDS-PAGE and analyzed by Western blot. E. HeLa membrane was photolabeled with 
95 nM BP-DDE, 55 nM BP-vicinal diol, or 140 nM BP-azobenzene and pulled-down 
with streptavidin beads. Samples were eluted twice with 40 ul of 2% hydrazine + 
0.05% SDS, 20 mM sodium periodate + 0.5% SDS, or 25 mM sodium hydrosulfite + 
0.05% SDS. Elutions 1 and 2 were combined. Samples were then eluted with 80 ul of 
2 mM biotin in Laemmli sample buffer at 70˚ C for 10 minutes (elution 3). Equivalent 
amounts of elutions 1 + 2 and elution 3 were loaded onto SDS-PAGE gel and 
analyzed by Western blot. F. HeLa membrane was photolabeled with 95 nM BP-DDE 
and pulled-down with streptavidin beads. Samples were eluted either with hydrazine 
or with heat: Sample A was eluted with 2% hydrazine + 0.05% SDS, samples B 
through F were eluted with various combinations of sample buffer, detergent, and heat.  
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SDS is not required for probe cleavage but is required for solubility of PS1-NTF 
The finding that PS1-NTF appeared on the Western blot when eluted with formic acid 
+ BSA in the absence of SDS suggested that SDS is not required for cleavage but is 
required for protein stability. To test whether SDS is required for probe cleavage we 
performed a series of experiments in which proteins were eluted with cleavage-
specific conditions in the presence or absence of SDS, beads were washed thoroughly 
with water, resuspended in sample buffer at room temperature, sample buffer was 
removed, and beads were eluted with 2 mM biotin in Laemmli sample buffer at 70˚ C 
for 10 minutes (Figure 4.3A-D). To our surprise, samples that were eluted with 
cleavage reagents in the absence of SDS showed a great deal of PS1-NTF in the 
subsequent sample buffer-resuspended fraction. On the contrary, proteins that were 
eluted with reagents containing SDS showed much less PS1-NTF in the subsequent 
sample buffer-resuspended fraction. This reveals that reagents lacking SDS are 
efficient at probe cleavage, but the hydrophobic PS1-NTF aggregates/sticks to the 
beads or tube and so does not get loaded onto the gel. With the addition of SDS, the 
reagents cleave the probe and the detergent forms a micelle that keeps PS1-NTF 
soluble. Therefore, the cleavage-specific reagents and detergent are both critical as 
they are performing entirely different but necessary functions during elution.  
To show that SDS alone does not elute proteins, we eluted beads with 0.05 or 0.5% 
SDS, washed beads with water, resuspended beads in Laemmli sample buffer (~1% 
SDS final), removed sample buffer, and eluted beads with 2 mM biotin in Laemmli 
sample buffer at 70˚ C for 10 minutes (Figure 4.3C and D, lanes C). We found that 
0.05 and 0.5% SDS alone do not elute proteins and Laemmli sample buffer elutes a 
very small fraction of protein. However, the amount of PS1-NTF eluted with sample 
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buffer is much lower than that eluted with cleavage reagents + SDS, suggesting that 
SDS alone does not elute proteins to any significant amount. 
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Figure 4.3. A. HeLa membrane was photolabeled with 95 nM BP-DDE and pulled-
down with streptavidin beads. Samples A and B were eluted two times with 2% 
hydrazine + 0.05% SDS (elutions 1 and 2). Beads were then washed with water and 
briefly resuspended in Laemmli sample buffer (resuspension). Sample buffer was 
removed and samples A and B were eluted a third time with 2 mM biotin in Laemmli 
sample buffer at 70˚ C for 10 minutes (elution 3). Sample C was eluted only with 2 
mM biotin in Laemmli sample buffer at 70˚ C for 10 minutes. B. HeLa membrane was 
photolabeled with 55 nM BP-vicinal diol and pulled-down with streptavidin beads. 
Samples A and B were eluted two consecutive times with 20 mM sodium periodate +/- 
0.5% SDS (elutions 1 and 2). Beads were then washed with water and briefly 
resuspended in Laemmli sample buffer (resuspension). They were then eluted a third 
time with 2 mM biotin in Laemmli sample buffer at 70˚ C for 10 minutes (elution 3). 
Sample C was eluted only with 2 mM biotin in Laemmli sample buffer at 70˚ C for 10 
minutes. C. HeLa membrane was photolabeled with 140 nM BP-azobenzene and 
pulled-down with streptavidin beads. Samples A and B were eluted two consecutive 
times with 25 mM sodium hydrosulfite +/- 0.05% SDS (elutions 1 and 2). Sample C 
was eluted two consecutive times with 0.05% SDS. Beads were then washed with 
water and briefly resuspended in Laemmli sample buffer (resuspension). They were 
then eluted a third time with 2 mM biotin in Laemmli sample buffer at 70˚ C for 10 
minutes (elution 3). D. HeLa membrane was photolabeled with 400 nM BP-DADPS 
and pulled-down with streptavidin beads. Samples A and B were eluted two 
consecutive times with 5% formic acid +/- 0.5% SDS (elutions 1 and 2). Sample C 
was eluted two consecutive times with 0.05% SDS. Beads were then washed with 
water and briefly resuspended in Laemmli sample buffer (resuspension). They were 
then eluted a third time with 2 mM biotin in Laemmli sample buffer at 70˚ C for 10 
minutes (elution 3). All samples were run on SDS-PAGE and analyzed by Western 
blot.
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Figure 4.3 
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BP-DDE large-scale photolabeling of PS1-NTF for LCMS analysis 
As a result of BP-DDE’s superiority at both labeling (Figure 4.1C, D) and eluting 
(Figure 4.2E) PS1-NTF, we used it in large scale photolabeling experiments in order 
to identify its binding site on PS1. First we established the optimal concentration of 
BP-DDE with which to label ANPP (HEK293 cells that overexpresses all four 
subunits of γ-secretase) membrane; the desirable concentration is one that saturates the 
γ-secretase sites without giving a high background signal, as established by blocking 
with BMS-708163. We determined that 100 nM of BP-DDE achieved high signal and 
low background, and increasing the concentration to 300 nM increased the noise but 
did not appreciably change the signal (data not shown). Briefly, 6 mg of ANPP 
membrane was photolabeled each with 100 nM BP-DDE with (+) or without (-) 10 
μM parent compound BMS-708163. Samples were pulled-down with streptavidin 
beads, eluted with 2% hydrazine + 0.05% SDS, and concentrated. The resulting 
labeling of PS1-NTF is both specific and abundant as can be seen when 1 μl of 60 μl 
concentrated sample was loaded on SDS-PAGE and Western blotted for PS1-NTF 
(Figure 4.4A). 
BP-TAMRA labels PS1-NTF and other potential protein targets 
We wondered whether BMS-708163 has protein targets other than PS-NTF. We 
designed BP-TAMRA, a BMS-708163-based probe that is conjugated to TAMRA for 
fluorescence (Figure 4.4B). BP-TAMRA appears to have targets other than PS-NTF, 
as photolabeling of HeLa membrane followed by in-gel fluorescence shows additional 
protein bands (Figure 4.4C). However, none of these bands, with the exception of PS-
NTF, can be marked as being specific, as they are not visibly competed by excess 
BMS-708163. When HeLa membrane was photolabeled by BP-TAMRA, followed by 
streptavidin pull-down and in-gel fluorescence, only the PS-NTF band was visible 
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(Figure 4.4D). This suggests that the other bands seen in Figure 4.4C may be non-
specific or may be γ-secretase interacting partners that are stripped off during the 
stringent wash conditions used for streptavidin pull-down. 
To identify BMS-708163 interacting proteins, we performed proteomic analysis on the 
large-scale labeling sample shown in Figure 4.4A. Samples with or without BMS-
708163 competitor were digested in solution either by LysC or trypsin. Over 500 
proteins were detected in both competed (+BMS-708163) and uncompeted (-BMS-
708163) samples, but the presence of the competitor compound significantly 
decreased the capture of PS1, PS2, and Nct (Figure 4.4E).  This result established that 
photoaffinity labeling of γ -secretase depended on specific binding of the probe to one 
of its subunits, the identity of which is PS and likely not Nct. The presence of the Nct 
hit can mean either that BP-DDE binds Nct directly or that Nct comes along for the 
ride as it is a PS interacting partner. Based on the finding that increased stringency of 
bead washing can dissociate Nct and other γ-secretase subunits from the BP-biotin-PS 
complex, we conclude that BP-DDE is stabilizing the γ-secretase complex and causing 
Nct to associate tighter with PS. Additional proteins significantly affected by the 
presence of competitor included epoxide hydrolase 1, a promiscuous target of 
benzophenone affinity labels, and lanosterol 14-α demethylase. Whether these proteins 
are being targeted by BP-DDE or are γ-secretase interacting partners remains to be 
investigated. 
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Figure 4.4. A. 6 mg of ANPP membrane was photolabeled each with 100 nM BP-
DDE in the presence (+) or absence (-) of 10 μM BMS-708163. Samples were pulled-
down, eluted with hydrazine + SDS, concentrated, and small quantity was used to 
detect PS1-NTF on Western blot. Input = 5 μg ANPP membrane B. Structure of BP-
TAMRA C. Left: 400 μg of HeLa membrane was photolabeled each with 20 nM BP-
TAMRA in the presence (+) or absence (-) of 1 μM BMS-708163. Samples were 
visualized by in-gel fluorescence Right: Coomassie blue stain of same gel D. 400 μg 
of HeLa membrane was photolabeled each with 20 nM BP-TAMRA in the presence 
(+) or absence (-) of 1 μM BMS-708163. Samples were pulled-down with streptavidin 
beads and visualized by in-gel fluorescence. E. Top: Effect of competitor compound 
BMS-708163 on the affinity capture of proteins from HeLa cell membrane preparation.  
Each point corresponds to one protein. Displacement of a protein to the right of the 
main population indicates that its capture was subject to competition by BMS-708163. 
Bottom: Top-scoring proteins (by Mascot protein score) from photoaffinity 
labeling/capture of HeLa cell membranes in absence and presence of competitor 
compound BMS-708163 (nd, not detected). 
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Figure 4.4 
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Figure 4.4 continued 
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BP-DDE binds PS1-NTF in its endoproteolytic loop between TMDs 6 and 7 
We next re-searched the data using a small database containing the sequences of the 
four recognized γ-secretase subunits together with the sequences of the highest-
scoring contaminant proteins already recognized in the sample. This search strategy 
carried an increased risk of false-positive identifications of photolabeled peptides, but 
also reduced the risk of missing a genuine modified peptide because of low scoring 
caused by untypical fragmentation in the MS/MS spectrum. In a search that permitted 
BP-DDE modification of Leu, Val, Ile, Met, or Ala and specified semitryptic cleavage 
(i.e. at least one end of any peptide identified must result from a tryptic cleavage), a 
plausible hit was reported for peptide 279-291 of PS1 modified by BP-DDE at 
Leu282. This peptide has the sequence NETLFPALIYSST, with the N-terminus 
resulting from a tryptic cleavage following Arg278. The nontryptic C-terminus of 
Thr291 is reported in UniProtKB (accession P49768) as an alternative C-terminus of 
the PS-NTF, consistent with it having existed in the protein before tryptic digestion. 
The mass spectrum and high-energy collisional dissociation spectrum of the detected 
product defined its identity. [M+2H]2+ obsd. had m/z = 1074.460;  the theoretical value 
for peptide 279-291 modified by BP-DDE is m/z = 1074.462 (mass discrepancy 1.9 
ppm). Simulation of the spectrum based on the product's proposed elementary analysis 
closely matched the experiment (Figure 4.5A). In the tandem mass spectrum (Figure 
4.5B), the site of modification was confined to Leu282, the fourth residue in the 
tridecapeptide, by detection of b2, b3, y8, and y9 ions lacking any modification by BP-
DDE. Dehydrated b5, b7, b8, and b9 ions bearing the modification were also fully 
consistent with modification having occurred at Leu282. However, the data did not 
include information indicating which atom in Leu282 provided the attachment site for 
BP-DDE. There is reason to believe that the α-carbon of Leu282 is the attachment 
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atom, as it is the most stable radical species. However, this does not exclude the 
carbons of the amino acid side-chain as potential targets for the benzophenone. 
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Figure 4.5. A. Top: Peak cluster identified as [M+2H]2+ of peptide 279-291 modified 
with hydrazine-cleaved residue of BP-DDE. Bottom: For comparison, simulated 
spectrum of proposed product, based on theoretical elementary composition of 
C98H134ClF3N20O27S plus two adduct protons. B. Tandem mass spectrum of modified 
peptide 279-291 with peak identities assigned according to the structure shown in the 
Inset.  Modification is shown as occurring at the alpha-carbon of Leu282, but the site 
of attachment with Leu282 is not known with certainty. C. Close-up view of the 
transmembrane region of γ-secretase in complex with DAPT (Bai et al., 2015a). 
DAPT not shown. Yellow – Pen2, cyan – PS, green – Nct, orange – Aph1. Leucine 
282 (shown in magenta) is facing the inside of the horseshoe. 
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Figure 4.5 
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Figure 4.5 continued  
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Figure 4.5 continued 
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Endoproteolysis of PS is required for BMS-708163 binding  
While we knew that BMS-708163 binds the endoproteolytic loop of PS, we did not 
know whether this binding required a loose fragment end, as in PS1-NTF, or a 
complete, uncleaved loop, as in PS-FL. To test whether BP-DDE labels PS1-FL, we 
photolabeled ANP24 (Hek293 cells that overexpress all three components of γ-
secretase except Pen2, resulting in an overabundance of PS-FL) membrane with 
various concentrations (20 nM – 500 nM) of BP-DDE in the presence or absence of 10 
μM BMS-708163. Samples were pulled-down with streptavidin beads, eluted with 
hydrazine, run on SDS-PAGE, and Western blotted for PS1-NTF. While we did see 
some labeling at the molecular weight that corresponds to PS1-FL, this labeling was 
not competed in the presence of BMS-708163, suggesting it is not specific (data not 
shown). This illustrated that BP-DDE binds PS1-NTF, but not PS1-FL.  
In order to eliminate the possibility that BMS-708163 is inhibiting endoproteolysis, 
we treated HeLa, SH-SY5Y, and SK-N-SH cells with 10 μM CBAP, BMS-708163, 
GSI-877 (a BMS-708163-based probe with a benzophenone and alkyne for azide-
alkyne cycloaddition), L458, and DMSO control for 4 to 7 days, lysed cells, ran lysate 
on SDS-PAGE, and Western blotted for PS1-NTF. We did not treat cells with BP-
DDE because the bulky biotin group would likely make the compound cell-
impermeable. CBAP, a compound that potently inhibits endoproteolysis, accumulated 
PS1-FL, but neither BMS-708163 nor GSI-877 were able to do the same (data not 
shown). This reveals that BMS-708163 and BMS-708163-based probes do not inhibit 
endoproteolysis. For more information on CBAP, see Chapter 2. 
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The binding sites of BP-DDE and DAPT overlap 
According to a recent high resolution cryo-EM structure, DAPT binds close to the 
active site of γ-secretase (Bai et al., 2015a). However, this finding is based largely on 
molecular modeling in areas of high flexibility that lack resolution, meaning the 
docking of DAPT may be imprecise. In order to gain greater insight into the binding 
of BMS-708163 on γ-secretase, we performed cross-labeling studies in which we 
looked for competition between BP-DDE and excess DAPT. When 1 μM DAPT and 
20 nM BP-DDE were incubated with HeLa membrane, photolabeling of PS1-NTF was 
strongly inhibited. However, up to 100 μM DAPT was unable to block photolabeling 
of PS1-NTF by the active site-directed probe, JC8. This finding can be explained by 
one of the following: 1. DAPT binds the hydrophobic stretch of the cytoplasmic loop 
of PS, close to Leucine 282, which was found to be the BP-DDE modified residue or 2. 
The binding of DAPT near the active site allosterically changes the conformation of 
the loop region in such a way that it no longer interacts with BP-DDE. While possible, 
explanation 2 seems unlikely, as the loop between TMDs 6 and 7 has been shown to 
modulate the active site, but the reverse has not been found. Additionally, DAPT is 
unlikely to bind the active site as it does not interfere with labeling of the active site-
directed probe, JC8. In all likelihood, and contrary to previous findings, DAPT shares 
a binding site with BP-DDE, which is in an allosteric region on the cytoplasmic side 
of the enzyme. 
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Figure 4.6. A. Cryo-EM structure of γ-secretase in complex with DAPT (Bai et al., 
2015a). Left: The reconstructed density for the entire complex. Density attributed to 
DAPT is shown in deep purple. Right: Schematic representation of the atomic model. 
TMs of PS1 are numbered. B. HeLa membrane was photolabeled with 20 nM of either 
BP-DDE or JC8 in the presence (+) of various concentrations of DAPT. This was 
compared to DMSO lanes. Parent compounds BMS-708163 or L458 were added at 1 
μM to completely block photolabeling. Lane in the middle is the protein ladder.  
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4.3 Conclusion and Discussion 
In this work we developed four cleavable linker probes for the study of γ-secretase and 
compared them side-by-side, revealing their potency and cleavage efficiency. Each 
probe, with the exception of BP-DADPS, can be used in future studies to explore γ-
secretase-small molecule interactions. However, the most efficient probe in our studies 
was BP-DDE: the high efficiency of BP-DDE-labeled PS1-NTF elution improved 
protein yield significantly over both heat eluted probes (BP-biotin) and probes with 
other cleavable linkers (BP-vicinal diol, BP-azobenzene, BP-DADPS). Given this 
advantage, we used BP-DDE to map the binding site of BMS-708163 on γ-secretase.  
We were able to localize BP-DDE binding to amino acids 279-291 of PS1. 
Furthermore, we identified Leu282 as the probe-modified residue. This probe-
modified region is adjacent to amino acids 291-292, which is one of the 
endoproteolytic sites of γ-secretase. In the process of endoproteolysis, PS-FL is 
converted into PS-NTF/CTF, an event necessary for activation of wild type γ-secretase. 
The 291-292 region is one of several potential cut sites, but a M292D mutation 
abolishes all endoproteolytic cleavage (Steiner et al., 1999b), confirming that this 
region is required for endoproteolysis. The M292D mutation mimics an FAD mutation, 
PS1ΔE9, in which the entire endoproteolysis site is deleted (amino acids 290-319), 
resulting in an active, endoproteolysis deficient γ-secretase (Thinakaran et al., 1996). 
The existence of these mutations suggests that the endoproteolytic loop is highly 
functional and may play an inhibitory role. While it was conceivable that BMS-
708163 was exerting its inhibitory activity by inhibiting endoproteolysis, this turned 
out to not be the case, as BMS-708163 has no effect on autocatalytic cleavage of PS-
FL and does not appear to bind PS-FL. It is possible, then, that BMS-708163 is 
inhibiting γ-secretase by mimicking the role of the inhibitory loop region of PS-FL.  
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A 3.4 Å cryo-EM reconstruction of γ-secretase gave tremendous insight into the 
enzyme’s structure, but some regions of this 20 pass transmembrane protein were 
missing in the model due to their disordered nature (Bai et al., 2015b). One of these 
missing regions was the hydrophilic and disordered surface loop between TMDs 6 and 
7 (amino acids 262-378), which houses the sites of endoproteolysis. When the 
structure was solved again with DAPT (a GSI) binding, some of these missing regions 
were resolved, so that the structure now reached amino acid 288 (Bai et al., 2015a). 
However, 289-377 remain unresolved. We propose that by solving the γ-secretase 
structure bound to BMS-708163, we can begin to stabilize these flexible regions in 
order to resolve them. 
BMS-708163 (avagacestat), an arylsulfonamide GSI, made it to human trials but was 
terminated in phase 2 due to high gastrointestinal toxicity, nonmelanoma skin cancer, 
and a worsening in cognition (Coric et al., 2012). While the compound was initially 
reported to be Notch-sparing (Gillman et al., 2010), later research showed that it had 
very little selectivity for APP over Notch (Chavez-Gutierrez et al., 2012;Crump et al., 
2012b). As a result, some of the observed toxicities were likely due to the compound’s 
inhibition of Notch signaling. A better understanding of the compound’s effect on γ-
secretase activity and its interaction with γ-secretase could have prevented the failed 
trials. In this work we have extended our understanding of BMS-708163 through 
structural insights into its target engagement. Specifically, we identified the binding 
site of BP-DDE, a probe form of BMS-708163, on PS. To our knowledge, this is the 
first time that the binding site of a GSI/GSM has been mapped at atomic resolution. 
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4.4 Methods 
Photolabeling for Western blot 
400 μg of HeLa membrane was pre-incubated with indicated concentrations of 
blocking compound (BMS-708163), where applicable, in the presence of 0.25% 
CHAPSO in 1 ml of PBS in a 24 well plate at 37˚ C for 20 minutes with gentle 
shaking. Indicated concentration of probe (BP-DDE, BP-vicinal diol, BP-azobenzene, 
BP-DADPS, or BP-biotin) was added and incubation was continued for 1 more hour. 
Samples were UV irradiated at 350 nm for 45 minutes on ice block, solubilized with 
1X RIPA for an hour, spun down at 15,700 xg for 10 min to pellet insoluble matter, 
and supernatants were pulled-down with 25 μl Streptavidin Plus UltraLink Resin. The 
streptavidin beads were washed 3X with RIPA, 2X with PBS, and 1X with cleavage 
specific buffer (BP-DDE – PBS; BP-vicinal diol – 100 mM sodium phosphate buffer 
pH 7.4; BP-azobenzene – 250 mM ammonium bicarbonate; BP-DADPS – PBS; BP-
biotin – PBS). Proteins were eluted with cleavage-specific conditions and/or with 2 
mM biotin in Laemmli Sample Buffer at 70˚ C for 10 minutes. Cleavage-specific 
conditions: Proteins were eluted 2 consecutive times, 30 minutes each, at 25˚ C with 
40 μl of cleavage specific reagents. Beads were then washed 3X each with 1 ml of 
0.1% SDS and eluted a third time with 2 mM biotin in Laemmli Sample Buffer at 70˚ 
C for 10 minutes. One sample was usually reserved for elution only with 2 mM biotin 
in Laemmli Sample Buffer at 70˚ C for 10 minutes. Where noted, proteins were 
washed 3X with 1 ml water (no SDS) between elutions 2 and 3. Laemmli Sample 
Buffer was added to samples and proteins were separated on SDS-PAGE. The desired 
proteins were detected via Western blot.     
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Photolabeling for LCMS 
6 mg of ANPP8 membrane protein was photolabeled each with 100 nM BP-DDE 
either with or without 10 uM BMS-708163. Photolabeling was performed identical to 
the above except with the addition of PI and PMSF and without CHAPSO. After UV 
irradiation samples were ultracentrifuged at 100,000 xg, supernatants were discarded, 
and pellets were resuspended in 500 μl RIPA buffer using TissuLyser. Samples were 
spun down at 15,700 xg for 10 min to pellet insoluble matter. 3 500 μl samples were 
combined and pulled-down with 30 μl streptavidin beads. Beads were washed 3X with 
RIPA and 3X with PBS. Beads were then eluted 2X with 40 μl of 2% hydrazine + 
0.05% SDS and washed 2X with 40 μl of water and these elutions and washes were 
combined and frozen. When all samples had been eluted (over the course of 1 week), 
they were all combined and concentrated on 10 kDa Amicon Ultra Centricon. Samples 
were concentrated ~24X, from 1440 μl down to 60 μl. Samples were sent to Pfizer and 
analyzed by LCMS.  
Photolabeling and blocking with DAPT 
400 μg of HeLa membrane was pre-incubated with indicated concentrations of 
blocking compound (BMS-708163, L458, or DAPT) in 1 ml of PBS in a 24 well plate 
at 37˚ C for 20 minutes with gentle shaking. 20 nM probe (BP-DDE or JC8) was 
added and incubation was continued for 1 more hour. Samples were UV irradiated at 
350 nm for 45 minutes on ice block and ultracentrifuged at 100,000 xg, supernatants 
were discarded, and pellets were resuspended in 500 μl RIPA buffer using TissuLyser. 
Samples were spun down at 15,700 xg for 10 min to pellet insoluble matter, 
supernatants were pulled-down and eluted with 2 mM biotin in Laemmli Sample 
Buffer at 70˚ C for 10 minutes as usual. 
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LCMS 
60 μl of each concentrated sample was treated with 60 μl of water and 480 μl of 
acetone, and incubated at -20° C overnight. The samples were then centrifuged at 4° C 
for 5 min at 15,000 xg, supernatants were discarded, and the residues were dried in a 
centrifugal evaporator. They were next redissolved in 40 μl of 8 M urea containing 5 
mM dithiothreitol and incubated at 60o C for 1 h, after which they were allowed to 
cool to room temperature, treated with iodoacetamide to a final concentration of 10 
mM, and then incubated for 1 h at room temperature. The samples were then treated 
with 40 μl of 0.05 M NH4HCO3 containing 0.2 μg of LysC (Wako) and incubated 
overnight at 37° C, after which they were treated with 160 μl of 0.05 M NH4HCO3 
containing 0.2 μg of trypsin (Promega sequencing grade), and incubated for 4 h at 
37oC. Following this, each sample was acidified to pH < 3 by addition of 
trifluoroacetic acid, and subjected to solid-phase extraction of peptides using 
StageTips (Rappsilber et al., 2007). The resulting samples were dried in the centrifugal 
evaporator, redissolved in 40 μl of 0.1% trifluoroacetic acid, and 7.5 μl portions were 
analyzed by liquid-chromatography/mass spectrometry using a Waters nanoAcquity 
system operating at 250 nl/min and a Q Exactive mass spectrometer (ThermoFisher 
Scientific). General proteomic searches were conducted using Proteome Discoverer 
2.0 (ThermoFisher Scientific) connected to the Mascot search engine (licensed from 
Matrix Science, Boston, MA) and targeting the UniProtHuman database supplemented 
with sequences of common protein contaminants (keratins, porcine trypsin, etc.). More 
specific searches for products of photolabeling were conducted against a custom-built 
small database containing the sequences of human γ-secretase subunits together with 
the sequences of known abundant contaminants and with conjugation of BP-DDE to 
selected amino acids allowed in the Mascot search as a variable modification. 
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Theoretical peptide masses and MS/MS fragmentations were calculated using 
GPMAW v. 9.5 (Lighthouse data, Odense, Denmark) and ChemBioDraw Ultra v. 13.0 
(Perkin-Elmer). 
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CHAPTER 5 
Thesis Implications 
γ-Secretase’s role in AD has positioned it in the spotlight for drug development. 
However, after years of diligent research and in spite of a strong genetic understanding 
of disease causes, there is still no FDA approved treatment for this age-related 
epidemic. Some have taken this dichotomy to mean that Aβ plaques are not the 
driving force of disease progression, reasoning that if we are not able to cure AD by 
inhibiting γ-secretase and reducing plaques, then maybe plaques are a consequence of 
disease and not its cause. Genetic evidence, however, tells an entirely different story. 
The presence of fully-penetrant, autosomal dominant FAD mutations in γ-secretase 
that increase the Aβ42:Aβ40 ratio, and even more convincingly, the presence of 
mutations in γ-secretase that decrease the Aβ42:Aβ40 ratio and protect from disease, 
are overt alerts of Aβ’s causative role in disease pathogenesis (Jonsson et al., 2012). 
The inability to treat/cure AD to date has likely been a result of inaccurate patient 
recruitment (many patients had a form of dementia other than AD), non-optimal drug 
dosages (patients were dosed intermittently instead of regularly), poorly understood 
drug toxicities, and less-than-ideal compound selection (non-selective GSIs were used, 
which caused mechanism-based toxicity). Many of these problems are now being 
addressed in the community and by our lab: Positron emission tomography (PET) 
brain scans can be used to ensure that we are enlisting the right patients in clinical 
trials, as doing AD trials on patients that do not, and never will, present with Aβ 
plaques is a sure way to destroy what could have been a good drug. Drug dosages 
remain a complex issue, but we have learned a great deal about drug administration 
from the clinical trials of BMS-708163 and LY450139. Off-target effects, while 
unavoidable, must be further studied if we are to make safe therapies. In this work we 
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explored the impact of GSIs/GSMs on SPP, a widely expressed enzyme that is 
required in eukaryotes and whose activity may be affected by drugs that target γ-
secretase (Gertsik et al., 2015). A thorough understanding of SPP-mediated pathways 
altered by drug treatment is vital for further GSI/GSM development. Finally, 
compound selection is a critical step in early stage drug development that requires 
more robust and a wider range of γ-secretase activity assays in order to attain accurate 
profiling of compound effects. Our lab has developed such assays and employed them 
to show that BMS-708163, which was initially reported as a Notch-sparing GSI 
(Gillman et al., 2010), was actually a nonselective GSI (Chavez-Gutierrez et al., 
2012;Crump et al., 2012b). Had this information come to light before clinical trials, I 
suspect it would have saved both patients and pharmaceutical companies from 
unnecessary suffering and spending. Furthermore, in this work we have mapped the 
binding site of BMS-708163 on γ-secretase, providing high resolution information for 
the way in which this compound interacts with its target. Such atomic resolution 
structure-function information can pave the way for rational drug design of 
GSIs/GSMs. 
In addition to providing valuable information for development of GSIs/GSMs as 
therapeutics, the work performed here has made important contributions to the study 
of complex transmembrane proteins for which high resolution structural information 
may not be available. First, we have shown that photoreactive transition state active 
site-directed probes can sense subtle changes in active site architecture of their target 
proteins. These probes are able to distinguish between PS1 and SPP, two proteins with 
very similar active sites. Furthermore, we showed that allosteric GSIs/GSMs have an 
impact on the active site conformations of PS1 and SPP, illustrating that structurally 
distinct compounds with different protein binding sites can engender active site 
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changes that are detectable with L458-based probes. Whether the structural changes 
observed here lead to alterations in activity of SPP remains to be determined. An 
increase in active site-directed probe labeling of enzyme does not necessarily translate 
to an increase in enzymatic activity, so we must be cautious in interpreting the 
photoaffinity results. We further used active site-directed probes to determine that SPP 
is a dimer in its active form. While both monomeric and dimeric forms of SPP have 
been found by various groups, it was unclear which of these forms was active and 
whether one or the other was an artifact of protein preparation. Our findings not only 
support the assertion that SPP is a dimer, but also illustrate an additional utility of 
L458-based probes – that is, their ability to be eluted with mild cleavage-specific 
conditions (in this case we used a disulfide linker, which was cleaved with a reducing 
agent) that minimize the perturbation to the proteins quaternary structure.    
We expanded on the ability of cleavable linker probes to label and elute target proteins 
under desirable conditions. Specifically, we made four different cleavable linker probe 
variants of BMS-708163 with the intention of identifying the binding site of BMS-
708163 on γ-secretase. We hypothesized that the acid-cleavable probe would work 
best, as its utility had been shown before and its elution with formic acid was 
compatible with LCMS (Szychowski et al., 2010). However, we were surprised to find 
that PS1 is unstable in acidic conditions, indicating that acid-cleavable probes are sub-
optimal for the study of γ-secretase. Through the synthesis of various linkers and the 
optimization of PS1 elution, we generated a set of tools for the study of γ-secretase 
and made important conclusions about the stability of the enzyme in various 
conditions. Importantly, we found that PS1 is highly stable in 2% hydrazine + 0.05% 
SDS. The high yield of PS1-NTF obtained from this cleavage condition can be widely 
useful for the study of γ-secretase. Moreover, we were successful in localizing the 
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binding site of BMS-708163 on γ-secretase, marking an important milestone in the 
study of GSI/GSM-γ-secretase interaction. Our lab had previously shown that 
structurally distinct GSIs/GSMs bind to different regions of PS1 (Crump et al., 2013), 
but the precise location of this binding was unknown. In this work we have 
circumvented the inherent difficulty of crystallizing a multipass transmembrane 
enzyme by using a combination of novel chemical biology and proteomics approaches 
to localize the binding site of BMS-708163 on γ-secretase. We have shown for the 
first time that it is possible to identify the amino acid residue to which these 
compounds bind. Our findings contribute not only to a better understanding of the 
structure and function of γ-secretase in order to elucidate disease mechanism and 
develop effective AD therapy, but also raise the bar for what is possible in the high 
resolution study of complex transmembrane proteins. 
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Chapter 6 
Materials and Methods 
6.1 Materials 
HeLa cell pellet (mid-log) for membrane preparation was purchased from Biovest. 
ANPP8 (HEK293 cells that overexpress PS1, Aph1, Nct, and Pen2) and ANP24 cells 
(HEK293 cells that overexpress PS1, Aph1, and Nct) were a gift from Dr. Sangram 
Sisodia and were grown in-house for membrane preparation and in-cell labeling. 
Biotin-PEG2-azide for azide-alkyne cycloaddition was purchased from ChemPep. 
Streptavidin Plus UltraLink Resin was purchased from Pierce. TAMRA azide was 
synthesized by Pfizer and provided as a gift. Protease Inhibitor cocktail was made in 
house from powders purchased from Sigma Aldrich, and used at final concentrations 
as follows: 1 mM benzamidine, 2.9 μM leupeptin, 5 μM antipain, 100 μM EDTA, and 
100 μM phenylmethanesulfonyl fluoride (PMSF). Typhoon Trio Variable Mode 
Imager (GE Healthcare) was used for in-gel fluorescence scans. Western blots were 
developed either with film or scanned with Odyssey CLx from LI-COR. Small scale 
membrane samples for photolabeling experiments were resuspended with TissueLyser. 
Primary antibodies for Western blot: anti-Aph1a 28-3600 was purchased from 
Invitrogen. Anti-PS1-CTF loop MAB 5232 was purchased from Millipore. Anti-Pen2 
18189 rabbit polyclonal was purchased from Abcam. Anti-PS1-NTF was provided by 
Dr. Min-Tain Lai (Merck Research Laboratories). Anti-SPP was made by Dr. Deming 
Chau in our lab by immunizing rabbits with a peptide epitode from the N-terminal 
region of SPP. Anti-NCT was similarly made in-house by immunizing rabbits with a 
NCT peptide. Secondary antibodies for Western blots scanned on Odyssey were 
purchased from LI-COR: IRDye 800 CW goat anti-rabbit and IRDye 680 RD goat 
anti-mouse. 
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AlphaLISA detection reagents such as streptavidin coated donor beads, anti-mouse 
acceptor beads and protein A coated acceptor beads for γ-secretase activity assay were 
purchased from PerkinElmer. 10-G3, which is an Aβ42 cleavage-specific antibody, 
was a gift from Dr. Douglas Johnson at Pfizer. G2-10, which is an Aβ40 cleavage-
specific antibody, was a gift from Merck Research Laboratories. SM320, the Notch1 
intracellular domain (NICD)-specific antibody, was generated by Dr. Deming Chau 
(Chau et al., 2012). Recombinant protein substrates Sb4 and N1-Sb1 were cloned from 
the cDNA of APP and Notch1, respectively (Tian et al., 2010a;Chau et al., 2012). 
These substrates are overexpressed with a biotin on one end for alphaLISA detection 
and a thrombin-cleavable MBP tag on the other, to allow for purification and optional 
removal. Proteins were purified with an amylose column and the AKTA Prime FPLC 
technology (GE Healthcare). AlphaLISA signal was detected with an EnVision 
multilabel plate reader (PerkinElmer).  
6.2 γ-Secretase activity assay 
In vitro activity assay has been described before (Tian et al., 2010a;Chau et al., 2012). 
A γ-secretase source, specifically 80 μg/ml of HeLa membrane, was incubated with its 
APP (Sb4) or Notch1 (N1-Sb1) substrate in the presence of 0.25% CHAPSO at 37˚C 
for 4 hours in the presence or absence of inhibitors or modulators. The amount of 
cleavage product generated was detected with a solution of cleavage specific antibody 
(G2-10 for Aβ40, 10-G3 for Aβ42, or SM320 for NICD) and alphaLISA protein A 
(Aβ42 and NICD) or alphaLISA anti-mouse acceptor beads (Aβ40) plus streptavidin 
coated donor beads from PerkinElmer. The reaction and detection mixtures were 
combined 1:1 (20 μl + 20 μl) in a 384 well plate, incubated overnight, and read the 
next morning with EnVision multilabel plate reader. 
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6.3 Photoaffinity labeling with active site-directed probes 
Photoaffinity labeling was performed as previously described (Placanica et al., 
2009a;Shelton et al., 2009). In a 24 well plate 400 μg HeLa membrane was incubated 
with 20 nM active site-directed probe (JC8, L646, GY4, or L505) and some 
concentration of blocking compound (GSI/GSM) in the presence of 0.25% CHAPSO. 
The total volume of each sample was 1 ml, made up with PBS. The concentration of 
DMSO in each reaction did not exceed 2.5% v/v. Plate was gently shaken at 37˚C for 
one hour. Next the plate was UV irradiated at 350 nm for 45 minutes on an ice block. 
Subsequently, samples were transferred to an Eppendorf tube and RIPA (50 mM Tris 
base, pH 8.0, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% deoxycholate) solubilized, 
rotating at room temperature for 1 hour. Samples were spun down at 15,700 xg for 10 
minutes to pellet insoluble matter. The supernatants were transferred to a dolphin-
nosed tube with 20 μl Streptavidin Plus UltraLink Resin and biotinylated proteins 
were pulled-down with rotation at 4˚ C overnight. The next day, samples were spun 
down at 100 xg and supernatant was removed. The streptavidin slurry pellet was 
washed 3X with RIPA and once with PBS. Proteins were eluted with Laemmli sample 
buffer + 2 mM biotin at 70˚ C for 10 minutes and separated on SDS-PAGE. The 
desired proteins were detected via Western blot. JC8 (Chun et al., 2004), GY4 (Yang 
et al., 2009), and L646 and L505 (Li et al., 2000b) were described previously. 
JC8, L646, GY4, and L505 are highly potent (IC50 ~ 1 nM) biotinylated photoaffinity 
probes based on L-685,458 (L458), a transition state active site-directed γ-secretase 
inhibitor with a hydroxyethylene dipeptide isostere (Figure 6.1A). These probes differ 
from one another in the location of the benzophenone, where the benzophenone was 
placed into various positions around the L458 backbone. Amino acids (termed “P”) on 
the N-terminal side of the scissile bond are numbered and amino acids on the C-
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terminal of the scissile bond are named with a number followed by a “prime” symbol 
(Schechter and Berger, 1967). By moving the benzophenone to different P sites, we 
created probes that can target various sub-sites of the enzyme active site. This 
technique is known as “photophore walking” (Shelton et al., 2009;Chau et al., 2012). 
Because crosslinking of the probe to the enzyme depends on the distance and 
orientation of the benzophenone to the contact residues, each probe has a different 
efficiency of insertion. Upon perturbation to the enzyme structure, this efficiency may 
change. Changes in efficiency of insertion reveal changes in the enzyme active site. 
Allosteric GSIs/GSMs may bind PS far from its active site, but nevertheless this 
binding may cause changes in the structure of the active site itself (Figure 6.1B). 
These changes are detectable with active site-directed probes described here. 
Depending on the structural perturbation, all of the probes may change in insertion 
efficiency, or only one may change. Importantly, addition of excess competitor, which 
is the parent compound (in this example, L458) without the benzophenone and biotin, 
should inhibit labeling entirely. This technique has been used to study changes in the 
enzyme active site architecture in the presence of GSIs, GSMs, and FAD mutations 
(Shelton et al., 2009;Tian et al., 2010a;Crump et al., 2011;Chau et al., 2012;Crump et 
al., 2012b;Gertsik et al., 2015). 
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Figure 6.1. A. Structures of biotinylated probes JC8, L646, GY4, L505, and parent 
compound L458. B. Active site-directed probe, with crosslinkable benzophenones 
(orange sun) in one of four possible positions, labels the active site (light blue) of  γ-
secretase at either the S1, S2, S1’, or S3’ subsites. The addition of a GSI or GSM 
(black star) changes the active site conformation of the enzyme, leading to a change in 
the interaction between the probe and its contact residues. C. Biotinylated, 
photoreactive, active site-directed probes are used to label the active sites of enzyme 
targets. Biotinylated proteins are pulled-down with streptavidin beads and visualized 
on a Western blot.
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6.4 Photoaffinity labeling with azide-alkyne cycloaddition (Figure 6.2) 
Probes with a benzophenone moiety for crosslinking and an alkyne moiety for 
conjugation to biotin for pull-down were incubated with 600 μg HeLa membrane and 
indicated concentration of GSI/GSM in a 24 well plate in 0.5 or 1 ml total volume, 
made up with PBS, shaking at 37˚ C for one hour. Next samples were UV irradiated at 
350 nm for 45 minutes on an ice block. Samples were ultracentrifuged at 100,000 xg 
to pellet the membrane fraction, supernatant was discarded and the pellet was 
resuspended in 200 μl PBS with the TissueLyser. Probe-labeled proteins were 
conjugated to biotin via copper catalyzed azide-alkyne cycloaddition (CuAAC): 
samples were rotated for 1 hour at room temperature with 1 mM CuSO4, 1 mM TCEP, 
0.1 mM TBTA, 100 μM biotin-azide, 5% t-butanol, and 1% DMSO in PBS. Samples 
were ultracentrifuged at 100,000 xg, supernatant was discarded and pellet was 
resuspended in 500 μl RIPA buffer using TissuLyser. Samples were spun down at 
15,700 xg for 10 minutes to pellet insoluble matter. The supernatants were transferred 
to a dolphin-nosed tube with 20 μl Streptavidin Plus UltraLink Resin and biotinylated 
proteins were pulled-down with rotation at 4˚ C overnight. The next day, samples were 
spun down at 100 xg and supernatant was removed. The streptavidin slurry pellet was 
washed 3X with RIPA and once with tris buffered saline, 0.1% tween-20. Proteins 
were eluted with 40 μl of 2 mM biotin in Laemmli sample buffer at 70˚ C for 10 
minutes and 20 μl of eluate was loaded and separated on SDS-PAGE. Proteins were 
transferred to PVDF membrane and probed with appropriate antibodies.  
6.5 Photoaffinity labeling with in-gel fluorescence (Figure 6.2) 
Probes with a benzophenone moiety for crosslinking and an alkyne moiety for 
conjugation to tetramethyl rhodamine (TAMRA) were incubated with 400 μg HeLa 
membrane and indicated concentration of GSI/GSM in a 24 well plate in 1 ml total 
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volume, made up with PBS, shaking at 37˚ C for one hour. Next samples were UV 
irradiated at 350 nm for 45 minutes on an ice block. Samples were ultracentrifuged at 
100,000 xg to pellet the membrane fraction, supernatant was discarded and the pellet 
was resuspended in 200 μl PBS. Probe-labeled proteins were conjugated to TAMRA 
via CuAAC: samples were rotated for 1 hour in the dark at room temperature with 1 
mM CuSO4, 1 mM TCEP, 0.1 mM TBTA, 60 μM TAMRA-azide, 5% t-butanol, and 
1% DMSO in PBS. Proteins were precipitated with cold acetone (80% acetone, 20% 
sample) at -20˚ C for 30 minutes. Samples were spun down at 15,700 xg for 10 
minutes to precipitate proteins and the pellet was washed once with 1 ml cold acetone. 
Acetone was removed, pellet was dried for 10 minutes and resuspended in Laemmli 
sample buffer without dye. Proteins were separated on SDS-PAGE, gel was washed 
and fixed with 20% methanol, and gel was scanned on Typhoon Trio Variable Mode 
Imager. The gel was then stained with Coomassie blue to ensure equal protein was 
loaded in all lanes. 
Probes that already had a TAMRA group directly attached did not require CuAAC. 
Following ultracentrifugation, these samples were resuspended in 250 μl 1% SDS in 
PBS and acetone precipitated. The rest was the same as above. 
Figure 6.2. Photoreactive probe with an alkyne is incubated with an enzyme source 
and covalently labels γ-secretase. Azide conjugated to a tag, such as a biotin or 
fluorophore, is “clicked” to the alkyne. The tag is used for protein isolation or 
visualization. 
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